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HOMEOSTATIC REGULATION OF INTERLEUKIN-4-MEDIATED 
CELL SIGNALING 
RIKHIA CHAKRABORTY 
ABSTRACT 
Cytokines are intracellular messengers that activate multiple signaling 
pathways and regulate cell survival, differentiation, migration, apoptosis and 
immune responses. We are investigating the homeostatic control of cytokine-
mediated cell signaling using interleukin-4 (IL-4) as a model cytokine. Protein 
tyrosine phosphorylation is essential for cytokine-dependent signal transduction 
through the Janus Kinase-Signal Transducer and Activator of Transcription (Jak-
STAT) pathway. Therefore, protein tyrosine dephosphorylation is a key 
mechanism providing the homeostatic control of the pathway. Here, we have 
shown for the first time that immediately following ligand-dependent activation, 
IL-4 receptor induces an intracellular calcium flux via insulin receptor substrate 
(IRS)-phosphoinositide 3-kinase (PI3K)-phospholipase C (PLC)-γ pathway which, 
in turn, induces protein kinase C (PKC)-dependent activation of NAD(P)H 
oxidase (NOX)5 that generates reactive oxygen species (ROS). IL-4 also induces 
NOX1-mediated ROS production via IRS-PI3K-Ras-related C3 botulinum toxin 
substrate (RAC) 1 pathway. Moreover, we have also demonstrated that IL-4-
generated ROS, in turn, promote IL-4 receptor activation by oxidatively 
inactivating protein tyrosine phosphatase 1B (PTP1B) that physically associates 
  
 
 
vii 
 
with and deactivates IL-4 receptor. In addition, we have shown that antioxidant 
enzymes peroxiredoxin II, IV and VI (Prx II, IV, VI) physically interact with the IL-4 
receptor and become oxidized by IL-4 generated ROS, thereby neutralizing IL-4 
generated ROS and compromising ROS-mediated amplification of IL-4 signaling. 
Cytokine-activated Jak-STAT pathway is believed to operate from cell surface to 
the nucleus via DNA-protein and protein-protein interactions without involving 
any second messengers. Here, we demonstrate, for the first time to our 
knowledge, a role for second messengers (ROS) in the amplification of Jak-
STAT signal transduction in IL-4-stimulated cells. Further, our data suggests that 
redox status of cells controls the magnitude of IL-4 receptor activation and signal 
transduction. 
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CHAPTER I 
INTRODUCTION 
 
1.1. Cytokines 
Cytokines are intracellular glycoprotein messengers, which activate 
multiple signaling pathways and regulate cell survival, differentiation, migration, 
apoptosis, and immune responses (Arai et al., 1990). The nomenclature of 
cytokines is based on their cellular sources, i.e. monokines (produced by 
mononuclear phagocytes), lymphokines (produced by lymphocytes) and 
interleukins (produced by leukocytes) (Rozwarski et al., 1994; Abbas and 
Litchman, 2003; Haque and Sharma, 2006). However, subsequent investigations 
have shown that a large number of cells produce interleukins, and secreted 
interleukins have a plethora of actions on different target cells. Cytokines are 
characterized by rapid secretion and very limited time of action either in a 
paracrine or autocrine fashion (Abbas and Litchman, 2003). Pleiotropy and 
redundancy render them very important in regulating multiple physiological 
functions, including the secretion and activity of other cytokines (Abbas and 
Litchman, 2003). They regulate their downstream effects through specific cell 
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surface receptors, where expression of the receptor largely determines the 
sensitivity of a particular cytokine action (Arai et al., 1990; Miyajima et al., 1992; 
Abbas and Litchman, 2003; Kishimoto et al., 1994).  
Cytokines are divided into four classes based on protein structures. They 
are hematopoietin (Type 1), IFN (Type 2), chemokine (Type 3) and TNF (Type 4) 
(Goldsby et al., 2003; Haque and Sharma, 2006). Cytokine include interleukins (1 
through 35) (Doan et al., 2007), erythropoietin (EPO), thrombopoietin (TPO), 
prolactin (PRL), growth hormone (GH), interferons (IFNs, both type I and II), 
granulocyte colony stimulating factor (G-CSF), granulocyte macrophage colony 
stimulating factor (GM-CSF), leptin, leukemia inhibitory factor (LIF), oncostatin M 
(OSM), ciliary neurotrophic factor (CNTF), cardiotrophin-1 (CT-1), cardiotrophin-
like cytokine (CLC) and tumor necrosis factor (TNF) (Haque and Sharma, 2006).  
Cell signaling by majority of cytokines are mediated by tyrosine-
phosphorylation of cognate receptors and downstream signaling proteins, which 
is initiated upon ligand binding to its cognate receptor. The physiologic control of 
cytokine receptor activation is primarily mediated by reciprocal activation of 
receptor-associated protein tyrosine kinases (PTKs) and protein tyrosine 
phosphatases (PTPs). 
1.2. Interleukin-4 (IL-4) 
IL-4 was discovered by Maureen Howard, William Paul (Howard and Paul, 
1982) and Ellen Vietta in 1982 (Isakson et al., 1982). The nucleotide sequence 
for human IL-4 was determined four years later confirming its similarity to a 
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mouse protein called B-cell stimulatory factor-1 (BCSF-1) or B cell growth factor 
(BCGF) (Rabin et al., 1986). IL-4 belongs to the hematopoietin family and is 
secreted by activated Th2-lymphocytes, basophils and mast cells (Nelms et al., 
1999; Haque and Sharma, 2006). 
1.3. Structure of IL-4 
IL-4 is a ~15-19 kDa soluble glycoprotein. Like all other hematopoietins, 
IL-4 has a four parallel α-helix (A, B, C, and D ) bundle structure, connected by 
loops, AB and CD (Powers et al., 1992; Smith et al., 1992; Walter et al., 1992; 
Wlodawer et al., 1992; Muller et al., 1994; Muller et al., 1995) (Figure 1). Specific 
regions of A and C primarily serve as binding epitope for IL-4 while interacting 
with high affinity receptor IL-4Rα (Kruse et al., 1993; Letzelter et al., 1998).  
Specifically glutamic acid (Glu9) and arginine (Arg88) residues of IL-4 is 
responsible for ligand binding to IL-4Rα (Wang et al., 1997). On the other hand 
interaction of IL-4 with the gamma common chain (γc) is mediated by defined 
regions located on helices A and D of IL-4 (Kondo et al., 1993; Kruse et al., 1993; 
Russell et al. 1993; Giri et al., 1994; Leonard et al., 1994; Letzelter et al., 1998; 
Asao et al., 2001). The interaction of IL-4 with the IL-13Rα1 is similar to its 
interaction with IL-4Rα chain, with the exception of an extra amino-terminal 
immunoglobulin-like domain (D1) in the former that allows formation of sheet-like 
contacts with the dorsal surfaces of IL-4 (LaPorte et al., 2008). 
 
 
4 
 
1.4. Functions of IL-4 
Biological functions of IL-4 in hematopoietic cells are very prominent. IL-4 
induces differentiation of Th2 cells (Figure 1.2) from naïve CD4+ T cells (Nelms et 
al., 1999) and suppresses Th1 differentiation and macrophage activation (Le 
Gros et al., 1990; Hsieh et al., 1992; Kopf et al., 1993; Nelms et al., 1999). 
Studies performed in IL-4- and STAT6 knockout mice shows significant changes 
in Th2 differentiation in helminth infection model (Nelms et al., 1999). The Th2 
cell in turn produces IL-4 and number of other cytokines including IL-5, IL-9, IL-
13, and IL-25. The subsequent major function of IL-4 and IL-13 is to induce 
proliferation and differentiation of B cells. During immunoglobulin class-switching, 
IL-9 favors the development of mast cells and IL-5 is involved in the development 
of eosinophils (Figure 1.2) (Nelms et al., 1999). 
IL-4 signaling transcriptionally upregulates the expression of IL-4Rα chain, 
major histocompatibility complex (MHC) class II and IgE receptor (CD23) genes 
in B cells (Noelle et al., 1984; Defrance et al., 1984; Ohara and Paul, 1988). In B 
lymphocytes, IL-4 is responsible for immunoglobulin class switching, IgE and 
IgG1 in mouse and IgE and IgG4 in humans (Coffman et al., 1986; Vitetta et al., 
1985; Gascan et al., 1991; Schindler et al., 1994; Zamorano and Keegan, 1998). 
IL-4- and IL-4Rα knockout mice show significant decrease in IgE production 
along with weak response during eosinophil-mediated host defense (Kuhn et al., 
1991; Noben-Trauth et al., 1997). IL-4 suppresses cell-mediated immune 
responses by opposing IFNγ effects on macrophages (Mokoena and Gordon, 
1985; Gordon, 2003). Also, in primary monocyte-derived macrophages (MDMs), 
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IL-4 signaling is associated with increased endocytosis through macrophage 
mannose receptor (MMR) (Montaner et al., 1999). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Crystal Structure of Human Interleukin-4. Structure accessed from 
Protein Data Bank (PDB: 2INT) and rendered using Pymol. The structure of IL-4 
is characterized by antiparallel juxtaposed α−helices and two end-to-end loops. 
(Adapted from J Biol Chem (1992) 267, 20371-20376).   
 
Functions of IL-4 on non-hematopoietic cells are not very well 
documented. Recent reports have shown that IL-4 suppresses apoptosis in 
glioma cells (Rahaman et al., 2005) and in colon cancer stem cells (Francipane 
et al., 2008), whereas in in vitro and in vivo models of human lung cancer IL-4 
shows significant antiproliferative effects (Topp et al., 1993). Other groups have 
shown overexpression of IL-4Rα in renal cell carcinoma, squamous cell 
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carcinoma of the head and neck, malignant glioma, AIDS associated Kaposi’s 
sarcoma and in breast cancer cell lines (Obiri et al., 1993; Puri et al., 1994; Obiri 
et al., 1994; Husain et al., 1997). Other than cancer cells, IL-4 largely modulates 
cells in the respiratory tract. IL-4 induces mucin 4 (MUC4) expressions in 
bronchoalveolar cells, whereas in nasal epithelial cells it induces MUC8 
expression (Seong et al., 2002; Damera et al., 2006). IL-4 has been implicated to 
have decisive roles in asthma and allergy. It has been shown to cause 
bronchoalveolar lavage (BAL) fluid eosiniphilia, airway hyperreponsiveness 
(AHR) and airway goblet cell hyperplasia in an IL-13 deficient allergic asthma 
model system (Perkins et al., 2006). In non-hematopoietic endothelial cells, IL-4 
selectively suppresses E-selectin expression and upregulates vascular cell 
adhesion molecule 1 (VCAM1) in the presence of another cytokine, tumor 
necrosis factor alpha (TNFα) (Thornhill et al., 1991; Bennett et al., 1997). 
1.5. IL-4 Receptor Complex 
1.5.1. IL-4 Receptor Complex Components and Expression 
IL-4 exerts its pleiotropic functions by activating intracellular signaling 
cascades through Type I (hematopoietic cells) and Type II ( non-hematopoietic 
cells)  receptor complexes  (Nelms et al., 1999) (Figure 1.3). The type I IL-4 
receptor complex consists of the IL-4Rα chain and the common γc chain (Mueller 
et al., 2002). The type II IL-4 receptor complex consists of the IL-4Rα and the IL-
13Rα1 chain (primary receptor chain for IL-13) (Callard et al., 1996).  
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Figure 1.2: IL-4 Functions as a Master Regulator of Allergic Inflammation. 
(Adapted from Abbas, A.K. and Litchman, A.H. (2003) Cellular and Molecular 
Immunology. Elseiver Science (USA) Philadelphia, PA). 
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The membrane proximal regions of IL-4 receptor subunits associate with tyrosine 
kinases of the Janus family (Janus kinase {Jak 1–3} and tyrosine kinase {TYK2}). 
IL-4Rα associates with Jak1 and γc with Jak3 (Dubois et al., 1998), whereas IL-
13Rα1 interacts with either Jak2 or TYK2, but not Jak3 (Nelms et al., 1999). 
Dimerization of the receptor subunits hyperactivates Jak, leading to 
phosphorylation of tyrosine residues in the cytoplasmic domain of IL-4Rα (Nelms 
et al., 1999). These phosphotyrosines then act as docking sites for signaling 
molecules containing protein tyrosine binding domains (PTBs) or Src homology 2 
(SH2) domains (Nelms et al., 1999). IL-4Rα chain also functions as a receptor 
component for another Th2 cytokine, IL-13. Thus, type II IL-4 receptor complex 
also functions as the receptor for IL-13. This receptor complex have been found 
to be expressed in brain, lung, muscle, placenta, kidney, epithelium and 
endothelium (Ohara and Paul, 1988; Lowenthal et al., 1988; Mehrotra et al., 
1998; Doucet et al., 1998; van der Velden et al., 1998; Henriques et al., 1998). 
Type II complexes are absent in T-cells, but are expressed in macrophages and 
B-lymphocytes (Nelms et al., 1999; Jiang et al., 2000).  
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Figure 1.3: Structure of IL-4-receptor complexes. 
(i) The type I complex involves IL-4Rα associated with tyrosine kinase Jak1 
and dimerizes with common chain γc associated with Jak3. Found mainly 
in hematopoietic cells. 
(ii) The type II complex involves IL-4Rα associated with tyrosine kinase Jak1 
and dimerizes with IL-13Rα1, which associates with either Jak2 or TYK2. 
Found mainly in non-hematopoietic cells. 
(Adapted from Annu Rev Immunol (1999). 17, 701-38). 
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1.5.2. Extracellular Domains of IL-4Rα Chain 
Like other hematopoietin receptor superfamily members, IL-4Rα chain 
consists of well-characterized fibronectin type III (FnIII) domains (D1&D2), 
connected by a linker domain (Mueller et al., 2002). Both D1 and D2 are 
composed of approximately 100 amino acid residues and form an 
immunoglobulin-like fold with seven beta strands organized into two beta sheets 
(Bazan, 1990; Haque and Sharma, 2006). A conserved Try-Ser-Try-X-Try-Ser 
(Try - tryptophan, Ser - serine and X - any amino acid) motif is present in the D2 
domain and is a characteristic of all Type I cytokine receptors (Mueller et al., 
2002).  
The crystal structure of Type I receptor complex reveals that the linker 
segment between D1 and D2 is composed of beta-sheets L2 and L5. In D1, 
these loops are flanked by L1 and L3, whereas in D2 it is flanked by L6 (Mueller 
et al., 2002). IL-4 binds in the groove (or elbow) formed between D1 and D2, and 
L2 and L6 interact with the bound IL-4 molecule (Meuller et al., 2002). The 
specific amino acid residues of IL-4Rα chain that interacts with IL-4 are Tyr-13, 
Ala-71, Tyr-183 and Tyr-127 of avocado cluster I and Asp-72 of avocado cluster 
II (Mueller et al., 2002).  
1.5.3. Intracellular Domains of IL-4Rα Chain 
The cytoplasmic domain of IL-4Rα chain also has precisely defined sub-
domain structures. Membrane proximal region or box I motif is predicted to be 
important for interaction with Jak1 (Nelms et al., 1999). The box I motif is acidic 
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in nature and mainly characterized by a proline rich sequence (Nelms et al., 
1999). Box I motif is followed by an insulin IL-4 receptor (I4R) motif (spanning 
amino acid residues 437-557 of the IL-4Rα), which closely resembles similar 
sequence elements in insulin like growth factor (IGF-1) and insulin receptors 
(Keegan et al., 1994b). The intracellular region of the IL-4Rα chain between 
residues 557 and 657 contains three conserved tyrosine residues at positions 
575, 603, and 631, which serve as gene induction domain (Ryan et al., 1996). 
Upon phosphorylation, these residues recruit STAT6. The membrane distal 
portion of the IL-4Rα consists of an immunoregulatory tyrosine-based inhibitory 
motif (ITIM) (Ile/Val-x-Tyr-x-x-Leu) that contains a conserved tyrosine residue at 
position 713 (Zamorano et al., 1998) (Figure 1.4).  
1.6. IL-4 Signaling through the IL-4 Receptor 
Binding of IL-4 to the IL-4Rα chain results in the recruitment of either γc or 
IL-13Rα1 to form the Type I or Type II receptor complex, respectively (Russell et 
al., 1993; Murata et al., 1998). IL-4Rα, γc and IL-13Rα1 remain constitutively 
bound to Jak1, Jak3 and Jak2 (or Tyk2), respectively (Johnston et al., 1994; 
Murata et al., 1996). Formation of the IL-4 receptor complex brings two Jak 
molecules to an appropriate proximity allowing them to trans-phosphorylate the 
invariant tyrosine residues located in their activation loops. This increases the 
catalytic activities of Jaks, which in turn overrides the receptor-associated PTP 
activity and initiates tyrosine phosphorylation-induced activation of IL-4Rα (Figure 
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1.3 and Figure 1.4). These phosphotyrosines then act as docking sites for 
signaling molecules  
 
 
Figure 1.4: Structure of Human IL-4Rα Chain. 
Tyrosine residues represents docking sites of different signaling proteins. The 
membrane distal portion of the IL-4Rα consists of an immunoregulatory tyrosine-
based inhibitory motif (ITIM) (Ile/Val-X-Tyr-X-X-Leu) that contains a conserved 
tyrosine residue at position 713. 
(Adapted from Annu Rev Immunol (1999). 17, 701-38). 
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containing protein tyrosine binding domains (PTBs) or Src homology 2 (SH2) 
domains, whereby proteins bind to an invariant stretch of Asn-X-X-Tyr497 (Asn - 
asparagines, Tyr -  tyrosine and X - any amino acid) (Trub et al., 1995). 
Phosphorylation of Tyr-497 leads to the binding and phosphorylation of 
IRS-1/2 molecules as well as other PTB domain containing proteins such as Shc, 
FRIP and DOK (Keegan et al., 1994a; Keegan et al., 1994b; Nelms et al., 1998), 
further  resulting in interaction with the p85 subunit of phosphatidylinositol 3’-
kinase (PI3K) (Nelms et al., 1998). p110 catalytic subunit of PI3K is activated 
following this interaction (Nelms et al., 1999). Detailed investigations using 
pharmacological inhibitors and p85α-/- mice have revealed the indispensable role 
of PI3K in IL-4-dependent growth and survival (Nelms et al., 1999).  These 
observations have led to the paradigm that the I4R motif is the growth promotion 
domain. 
On the other hand signal transducer and activator of transcription 6 
(STAT6) is recruited as a result of phosphorylation of tyrosine residues 575, 603, 
and 631 by activated Jaks. STAT6 is subsequently phsophorylated at Tyr-641, 
which results in its homodimerization (Mikita et al., 1996; Darnell, 1997) and 
translocation to the nucleus. In the nucleus, activated STAT6 dimers bind to 
promoters of IL-4-responsive genes harboring the TTC-N4-GAA GAS (IFNγ 
activated sequences) (Ihle, 1996) (Figure 1.5). STAT6 is responsible for 
regulating the expression of a wide array of genes, including CD23, IL-4Rα, IgE 
and IgG1 in mice, IgE and IgG4 in human, and E4 binding protein-4 (E4BP4) 
(Vietta et al., 1985; Coffman et al., 1986; Defrance et al., 1987; Ohara and Paul, 
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1988; Gascan et al., 1991; Schroder et al., 2002; Chen et al., 2003; Kelley-Welch 
et al., 2003). 
Additionally, activated Jaks also phosphorylates Tyr-713 in the ITIM 
(Zamorano et al., 1998). Experimental evidences have shown ITIM to be involved 
in negative regulation by binding to tyrosine and lipid phosphatases (Muta et al., 
1994; Burshtyn et al., 1996). Studies have revealed that SRC homology-domain 
2 (SH2) containing phosphatase-1 (SHP-1) is involved in the negative regulation 
of IL-4-dependent activation (Haque et al., 1998; Hanson et al., 2003), 
suggesting the association of a tyrosine phosphatase with the Tyr-713 residue in 
the ITIM. Interestingly, SHP-1 has also been shown to interact with IL-4Rα (Imani 
et al., 1997). 
1.7. Multiple Mechanisms of Homeostatic Regulation of IL-4 Signaling 
IL-4 executes multiple functions by activating two major (IRS-PI3K, Jak-
STAT6) and two minor (MAPK, SHC-GRB2) pathways. IL-4 signaling is regulated 
by complex homeostatic mechanisms (Haque and Sharma, 2006). IL-4 signaling, 
like most other cytokine signaling pathways, is limited in duration and magnitude 
(Haque and Sharma, 2006); hence requiring a tight regulation of biochemical 
events that activate and amplify the signal initiated by ligand binding to the 
cognate receptor and additional mechanisms that attenuate the signaling 
pathways. 
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1.7.1. Negative Regulation of IL-4 Signaling 
The Jak-STAT pathway is negatively regulated at multiple levels (Starr 
and Hilton, 1999).  
1.7.1.1. Decoy Receptors 
A receptor antagonist may compete with the cytokine for receptor 
occupation or a decoy receptor may compete with the functional receptor for 
cytokine binding, and block the initiation of cytokine signaling.  Alternate splicing 
of mRNA generates receptor transcripts that encode extracellular domain 
containing leader signals but not transmembrane domains, and are secreted by 
producer cells.  Soluble IL-4Rα detected in biological fluids is produced by an 
alternate splicing of mRNA (Chilton and Fernandez-Botran, 1993; Heaney and 
Golde, 1996; Levine, 2004). It has been shown that IL-13Rα2 can also inhibit IL-4 
signaling through the type II receptor complex comprised of IL-4Rα and IL-13Rα1 
(Rahaman et al., 2002). 
1.7.1.2. Protein Tyrosine Phosphatases (PTPs) 
Protein tyrosine phosphorylation is a dynamic and reversible biochemical 
events responsible for the regulation of multiple intracellular signaling pathways 
(Tonks, 2006), including the Jak-STAT signaling pathway. In this event, the 
forward reaction is driven by PTKs and the reverse reaction by PTPs (Tonks, 
2006).   
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PTPs are receptor-like and non-receptor enzymes possessing highly 
conserved catalytic domains specific for phosphotyrosine hydrolysis, which make 
them attractive molecules in the regulation of receptor tyrosine kinases-mediated 
signal transduction (Haj et al., 2003). PTPs contain essential cysteine residues in 
a signature active site motif [His-Cys-X-X-Gly-X-X-Arg(Ser/Thr)] (His= histidines, 
Cys= cysteine, Gly= glycine, Arg= argininie, Ser= serine, Thr= threonine, and X= 
any amino acid residue) that must be in a reduced state for proper catalytic 
activity (Maehama et al., 2001; Kwon et al., 2004).  
Given the important roles played by PTPs in signal attenuation and data 
obtained from earlier studies, Haque et al. predicted the existence of separate 
cohorts of phosphatase, PTP-x that dephosphorylates the Jaks, the cytokine 
receptors and PTP-y, which dephosphorylates the STAT molecules that have 
already translocated to the nucleus (Haque et al., 1995; Haque and Sharma, 
2006). Subsequent work by the same group has elucidated Shp-1, an SH2 
domain containing PTP, being responsible for attenuating the Jak-STAT 
pathway; likely acting as PTP-x. (Haque et al., 1995; Haque et al., 1998; Haque 
and Sharma, 2006). Work from other laboratories have identified CD45 as a 
phosphatase important in downregulating Jak-STAT signaling in hematopoietic 
cells (Irie-Sasaki et al., 2001; Hermiston et al., 2003; Haque and Sharma, 2006).  
TC-PTP has been indicated to be the phosphatase responsible for 
downregulating the Jak-STAT pathway in non-hematopoietic cells (ten Hoeve et 
al., 2002; Bourdeau et al., 2005). 
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Figure 1.5: Schematic Representation of IL-4-dependent Major Signaling 
Pathways. 
(Adapted from Annu Rev Immunol (1999). 17, 701-38). 
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1.7.1.3. Ubiquitin-mediated Proteosomal Degradation 
Proteolytic degradation of signaling proteins also causes attenuation or 
termination of cytokine signals. Ubiquitin mediated proteolysis also 
downregulates Jak-STAT signaling, even though much remains unknown about 
the physiological significance of these proteolytic events (Nelms et al., 1999).  
1.8. Reactive Oxygen Species (ROS): Role as Second Messengers 
Under normal physiological conditions, signal transduction pathways 
mediated by cytokines and growth factors are limited in both magnitude and 
duration (Haque and Sharma, 2006). Over the last few years regulation of 
cytokine mediated signal amplification has been a major area of interest, where 
some of the reports suggest reactive oxygen species (ROS) as being a major 
factor in the determination of magnitude of signal amplification (Sundaresan et 
al., 1995; Bae et al., 1997; Finkel, 1998; Rhee, 1999; Ushio-Fukai et al., 1999). It 
has been shown that non-phagocytic cells produce ROS in response to cytokines 
and growth factors (Rhee et al., 2000) and inhibition of ROS generation causes 
signal attenuation of insulin, PDGF, EGF and angiotensin II pathways 
(Sundaresan et al., 1995; Bae et al., 1997; Finkel, 1998; Rhee, 1999; Ushio-
Fukai et al., 1999). The current work is perhaps the first report where we are 
documenting the evidences of ROS contributing to IL-4-mediated signal 
amplification. The work also provides evidence for a role of ROS as second 
messengers in Jak-STAT signaling, which was long believed to proceed only by 
DNA-protein and protein- protein interactions without the involvement of any 
second messengers. 
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ROS consist of a variety of reduced form of oxygen, including superoxide 
anion (O2–), hydrogen peroxide (H2O2) and hydroxyl radical (OH•) (Finkel, 1998; 
Rhee, 1999; Lambeth, 2004). ROS are inevitably generated in all organisms 
living in aerobic conditions. Growth factors and cytokines execute their actions by 
binding specific cell-surface receptors that initiate intracellular signaling cascades 
(Leaman et al., 1996; Darnel, 1997; Brivanlou and Darnell, 2002). By inactivating 
phosphatases, reactive oxygen species can amplify signal transmission or 
possibly alter the phosphorylation status of signaling kinases (Denu and Tanner, 
1998). PTP1B possesses a low pKa active site Cys215 (Lohse et al., 1997) 
rendering it sensitive to cellular ROS (Denu and Tanner, 1998; Rhee et al., 
2005). Specifically, it has been shown that ROS can reversibly inactivate PTPs in 
cells that are stimulated by cytokines or growth factors (Lee et al., 1998; Meng et 
al., 2002; Kwon et al., 2004; Rhee et al., 2005). The mechanism of PTP1B 
inactivation by ROS involves the reversible oxidation of the catalytic cysteine, 
thereby resulting in an inactive sulfenic acid intermediate (Kwon et al., 2004). 
Cys 215 may therefore serve as a regulatory switch, whereby in the presence of 
ROS, the tyrosine phosphatase activity is reversibly inhibited by the formation of 
a sulfenic acid (-SOH) intermediate at residue 215. The consequence of this 
event is the upregulation of receptor tyrosine kinase (RTK)-dependent signal 
transduction. Phosphatase activity can be restored following the removal of ROS 
by various cellular antioxidant systems, including catalase, glutathione 
peroxidases, peroxiredoxins and superoxide dismutases (Margis et al., 2008). 
Signal amplification by ways other than ligand binding can positively cooperate 
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with the canonical signaling molecules in upregulating IL-4 signaling, thus making 
it imperative to investigate the role of ROS in the IL-4 signaling pathway. 
1.8.1. Sources of ROS 
The sources of ROS, such as O2•-, OH•, H2O2 and others, can be either of 
exogenous or endogenous origins. Endogenously, ROS are produced by NADPH 
oxidases, lipoxygenase, xanthine oxidase, and cytochrome P450 (Rhee et al., 
2003).  Heavy metal ions, γ-radiation, and UV light can also induce ROS 
formation. One of the main sources of ROS in many cell types is the 
mitochondrial respiratory chain (Rhee et al., 2003).  
NADPH oxidase (NOX) was originally identified as a phagocytic leukocyte 
specific enzyme, but subsequently similar oxidase complexes have been 
characterized in non-phagocytic cells, such as vascular endothelial, smooth 
muscle cells and fibroblasts (Zulueta et al. 1995). In phagocytes, Nox is activated 
by chemokines or phagocytic particles, which induce assembly of cytosolic 
subunits, Ras-related C3 botulinum toxin substrate 2 (Rac2), p47 phagocytic 
oxidase (p47phox) and p67 phagocytic oxidase (p67phox) with membrane-bound 
components, p22 phagocytic oxidase (p22phox) and glycoprotein 91 phox 
(gp91phox), to generate O2•- from O2 and NADPH (Lambeth, 2004). This so 
called respiratory burst leads to the release of ROS from the cell, which is an 
important feature of immune defense against bacterial and fungal infections 
(Holmes et al. 1967). Released O2•- may be converted to H2O2, which in turn is a 
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substrate for myeloperoxidase, which subsequently produces hypochlorous acid 
and other strong oxidants (Winterbourn et al. 2000).  
1.8.2. NADP(H) Oxidases (NOX): The ROS Generators 
It was long believed that phagocytes were the only source of intracellular 
ROS generation. But detection of low amounts of ROS in non-phagocytic cells 
was reported using sensitive and quantitative detection tools (Lambeth, 2004). 
Use of small molecule inhibitors showed that a flavoprotein (similar to gp91phox) 
is responsible for intracellular ROS generation in non-phagocytic cells (Lambeth 
et al., 2000; Lambeth, 2004). Until now, seven different isoforms of 
NOXes/DUOX are known (Lambeth, 2004). The first of the NOX homologues of 
gp91, NOX1 was cloned from colonic epithelial cell complementary DNA library 
in 1999 (Suh et al., 1999). NOX 3 and NOX 4 were next identified (Geiszt et al., 
2000; Shiose et al., 2001). Both NOX3 and NOX4 generate high levels of ROS 
when exogenously expressed in cells (Geiszt et al., 2000; Shiose et al., 2001; 
Geiszt et al., 2003). NOX1, on the other hand, require co-expression of 
regulatory subunits to show comparable amounts of ROS generation when 
expressed in cells (Banfi et al., 2003; Geistz et al., 2003). 
Given the regulated amounts of ROS expressed in non-phagocytic cells, it 
might be rationalized that intracellular ROS are involved in regulatory or signaling 
pathways (Lambeth, 2004). ROS can participate in post-translational modification 
of proteins and have regulatory effects on signal transduction pathways. One 
such example is ROS-mediated reversible oxidation of the active site cysteine in 
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tyrosine phosphatases and PTEN (phosphatase and tensin homologue) (Lee et 
al., 1998). Subsequently the oxidized cysteine hydrolyses the 3-phosphate group 
from the bioactive lipid phosphatidylinositol 3,4,5-trisphosphate (Lee et al., 1998), 
inhibiting both tyrosine phosphatases and PTEN. Most of the ROS-mediated 
effects are reversible, thus providing a viable option for ROS to participate in 
signaling and regulatory pathways.  
1.8.2.1. Types of NOXs 
All NOX family members are transmembrane proteins that transport 
electrons across biological membranes to reduce oxygen to superoxide. In 
accordance with this preserved function, there are conserved structural 
properties of NOX enzymes that are common to all family members. Starting from 
the COOH terminus, these conserved structural features include 1) an NADPH-
binding site at the COOH terminus, 2) a FAD-binding region in proximity of the 
most COOH-terminal transmembrane domain, 3) six conserved transmembrane 
domains and 4) four highly conserved heme-binding histidines, (two in the third 
and two in the fifth transmembrane domain). Additional features, such as EF 
hands, an additional NH2-terminal transmembrane domain, and/or a peroxidase 
homology domain, are limited to some of the family members and are discussed 
below (Lambeth et al., 2004) (Figure 1.6). 
The nature of domains present in NOXs in addition to the basic gp91phox 
domain forms the basis of classification of NOX into three basic classes. NOX1, 
NOX3 and NOX4 all resemble gp91phox in size and structure (Lambeth et al., 
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2000). All three also possess the electron transfer centers required for electron 
transfer from NADPH to molecular oxygen to form O2•-. Subsequently, two O2•- 
molecules react to generate H2O2. The presence of a calmodulin-like domain, 
containing four calcium binding sites, at the amino-terminal region of gp91phox 
constitutes NOX5 (Banfi et al., 2001). Banfi et al. has shown that ionomycin, a 
calcium ionophore, can activate exogenously expressed NOX5 in cells (Banfi et 
al., 2001).  The DUOX enzymes differ from NOX5 by having an additional amino 
terminal peroxidase homology domain (Lambeth, 2004; De Deken et al., 2000). 
The peroxidase domains of DUOX and myeloperoxidase are homologous, but 
the former also has an inherent myeloperoxidase activity (Zeng and Fenna, 
1992). DUOX is thus capable of both generation and elimination of ROS by its 
own peroxidase activity.  
1.8.3. Regulation of NOX-dependent ROS Production 
Intricate regulation by regulatory subunits is the landmark of NOX-
mediated ROS generation (Figure 1.7). Phox is regulated by membrane-
associated p22phox. gp91phox and  p22phox form a complex, called 
flavocytochrome b558,  whereby the association complementarily stabilizes each 
other (Lambeth, 2004). The C-terminal proline rich sequence of p22phox 
interacts with the cytosolic regulatory subunit p47phox via the two SRC-
homology 3 (bis-SH3) domains (Ago et al., 2003; Groemping et al., 2003). 
p67phox, p40phox and the GTPase RAC (RAC1 and/or RAC2) are the other 
cytosolic regulatory subunits (Vignais et al., 2002). Assembly of the membrane 
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and cytosolic regulatory subunits with gp91phox activates the enzyme (Lambeth 
et al., 2000). In the inactive state p47phox does not interact with the p22phox, 
which is achieved by the bis-SH3 domain and an autoinhibitory region in 
p47phox (Ago et al., 2003). In the active state, p40phox and p67phox normally 
complex with p47phox in the cytoplasm. 
RAC is kept in an inactivated state by the inhibitory protein RhoGDP-
dissociation inhibitor. Activation of NOX occurs through different steps that 
cumulatively result in the assembly of the membrane and cytoplasmic 
components with gp91phox, thereby triggering ROS generation (Han et al., 1998; 
Nisimoto et al., 1999). The rate-limiting step in O2•- generation is the electron 
transfer between NADPH and bound flavin adenine dinucleotide (FAD), which is 
potentiated by the p67phox activation domain (Nisimoto et al., 1999). 
NOX4 is usually constitutively active and does not require cooperative 
effect of regulatory subunits (Geistz et al., 2000). It has been suggested that 
NOX4 activity is either regulated by its expression level or by direct post-
translational modification. Given the calcium binding domains in NOX5 and the 
DUOX enzymes (DUOX 1 and DUOX 2), their regulation is mediated by 
intracellular calcium levels (Dupuy et al., 1999; Banfi et al., 2001). 
As is evident, cells have evolved detailed and distinct regulatory 
mechanisms of intracellular ROS generation. This might explain the important 
role of intracellular levels of ROS in modulating different signal transduction 
pathways. 
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Figure 1.6: Structure of NOX and DUOX Family of Enzymes. 
(Adapted from Curr Opin Hematol (2002) 9, 11–17) 
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1.8.4. Effects of ROS 
In multicellular organisms, ROS-induced damages to DNA can be very 
harmful since they can lead to mutations, which are then passed on to future cell 
generations. However, more commonly ROS damage evokes apoptosis or 
necrosis, which can be very severe and extensive leading to major tissue 
damage (Raffray and Cohen, 1997). More importantly, ROS has been historically 
known to be produced by phagocytic cells in order to mount an immune response 
to microbial infections (Holmes et al. 1967). ROS generated in non-phagocytic 
cells as a result of growth factor and cytokine signaling has been shown to 
manipulate the functions of transcription factors, protein kinases and 
phosphatases, phospholipases, ion channels and G-proteins (Burdon, 1995; 
Thannickal and Fanburg, 2000; Martindale and Holbrook, 2002). Reversible 
inactivation of PTPs and PTENs by posttranslational oxidative modifications in 
cells treated with cytokines and growth factors perhaps account for the most 
important role of ROS in cell signaling pathways (Rhee et al., 2005). Intracellular 
ROS have also been associated with stress-activated protein kinase (SAPK) and 
protein kinase C (PKC) activities (Janssen-Heininger et al. 1999, Liu et al. 2000). 
These provide tools for wide regulatory possibilities in cell growth, proliferation, 
apoptosis, differentiation and cellular metabolism. Several transcription factors 
have been reported to be redox sensitive e.g. nuclear factor κβ (NFκβ), activator 
protein 1 (Ap1) and specificity protein 1 (Sp1) (Toledano & Leonard 1991, Li et 
al. 1994, Ammendola et al. 1994). Clearly, further studies are needed to reveal 
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the detailed role and mechanisms of the elevated ROS concentrations during cell 
signaling processes.  
1.9. Oxidative Damage by ROS and Need for ROS Elimination 
Protein oxidation results from the reaction of ROS with both amino acid side 
chains and peptide backbone (Berlett et al., 1997). Oxidative damage to proteins 
can take place within almost all amino acids; being the most reactive with sulfur 
amino-acid containing proteins (Berlett et al., 1997). Certain oxidations of 
proteins are reversible; oxidative modification of cysteine and methionine can be 
reversed by enzymatic systems like glutaredoxin/glutathione/glutathione 
reductase systems or thioredoxin/thioredoxin reductase systems. The reversibility 
of protein oxidation is very important in cell signaling pathways and it is 
considered one of the main mechanisms of redox signaling (Droge, 2002). 
Changes in the local redox state of protein sulfhydryls lead to conformational 
changes that, depending on the protein, can either decrease or increase DNA 
binding activity, or promote protein complex formations which are necessary for 
signal transduction or transcription to proceed (Droge, 2002). Irreversibly 
oxidized proteins mainly constitute hydroxylated and carbonylated amino acid 
derivates. These moieties are chemically stable; hence, protein carbonyl groups 
are used as biomarkers of oxidative stress. Accumulation of protein carbonyls 
has been observed in Alzheimer’s disease, diabetes and inflammatory bowel 
disease, among others (Dalle-Donne et al., 2003). Oxidized proteins are 
generally less active, and expose hydrophobic amino acids at their surface, 
leading to changes in protein conformation and activity (Friguet, 2006). 
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Elimination of mildly oxidized proteins is preferentially done by the 20s 
proteasome in an ATP-and ubiquitin-independent manner (Grune et al., 1995; 
Grune et al., 2003). However, strong protein oxidation and/or a strong oxidative 
stress condition lead to proteasome inhibition (Grune et al., 1995). Accumulation 
of damaged proteins due to proteasome inhibition has been associated with 
metabolic perturbations, aging and different pathologies including Parkinson’s 
and Alzheimer’s diseases (Ciechanover, 2005; Reed et al., 2007), but little is 
known about proteasome inhibition in carcinogenesis.  
 
Enzyme Regulator(s) 
NOX1 p22phox NOXO1, RAC1, NOXA1 
NOX2 p22phox p47phox, RAC1/2, p67phox 
NOX3 p22phox NOXO1, RAC1 
NOX4 p22phox  
NOX5 
 
Calcium 
DUOX1 
 
Calcium 
DUOX2 
 
Calcium 
Figure 1.7: Regulator proteins of NOX and DUOX Family of Enzymes. 
(Adapted from Nat Rev Immunol (2004) 4, 181-189). 
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1.9.1. Elimination of ROS 
ROS are detoxified by antioxidants, including non-enzymatic molecules 
like carotenoids, vitamin C and vitamin A, and distinct enzymatic systems (Margis 
et al., 2008). There are four key redox regulation systems: the superoxide 
dismutases, catalase, glutathione peroxidases and the thioredoxin peroxidases 
(Flohe and Ursini, 2008).  
1.9.1.1. Superoxide Dismutase (SODs) 
SODs degrade the highly reactive O2·- to the less reactive H2O2 (Mates et 
al., 1999).  
                                O2·-     +  O2·-    +  2H+                H2O2  +  O2  
There are three predominant forms of SODs in humans. Copper-zinc SOD 
(CuZnSOD) preferentially localized in the cytosol, manganese SOD (MnSOD) 
present exclusively in the mitochondrial matrix, and extracellular SOD (ECSOD) 
(Mates et al., 1999). MnSOD is indispensable as evident by postnatal fatality of 
MnSOD-/- knockout mice within 3 weeks of birth. In comparison, CuZnSOD-/- and 
ECSOD-/- mice develop normally (Carlsson et al., 1995). Cells become resistant 
to hyperoxia, cigarette smoke, cytokines, irradiation and oxidants when MnSOD 
is ectopically overexpressed in them (St. Clair et al., 1991; Lindau-Shepard et al., 
1994; St. Clair et al., 1994). The other prevalent antioxidant enzymes, catalase, 
glutathione peroxidases (GPxs) and peroxiredoxins (Prxs) are responsible for 
detoxifying the H2O2 produced as a result of SOD activity.  
SOD 
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1.9.1.2. Catalase 
Catalase was originally identified by Jons Jacob Berzelius (Berzelius, 
1836) and Lowe named it in 1900 (Lowe, 1900). It is located mostly in the 
peroxisomes, and to some extent in cytoplasm and mitochondria (Hillar et al., 
2000).  
                           H2O2                        H2O   +   ½ O2 
Because it can evolve molecular oxygen, catalase is known to degrade hydrogen 
peroxide by dismutation (Zamocky et al., 2008). Catalase interacts with 
NADH/NADPH, which inhibits its inactivation but does not contribute to the 
catalytic activity of the enzyme (Kirkman and Gaetani, 1984). Catalase can 
render both protective or damaging effects on the cells in a context-dependent 
fashion, a fact elucidated by the observation that catalase can generate ROS in 
response to UVB radiations in keratinocytes (Heck et al., 2003).  
1.9.1.3. Glutathione Peroxidases (GPxs) 
This system uses NADPH as an ultimate electron donor and requires 
selenium as a cofactor (Mates et al., 1999). It contains a key enzyme belonging 
to a pyridine nucleotide disulfide oxido-reductases family and a small redox-
reactive peptide. Glutathione reductase reduces glutathione, which in turn 
controls the redox status of cells. Other components in this system include 
glutaredoxin (Grx), a small protein that specifically removes glutathione 
molecules from mixed disulfides formed between glutathione and other 
molecules. GPxs have different isoforms, each 
CATALASE 
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                             H2O2 + 2GSH                   2H2O   +   GSSG 
having different locations (Fourquet et al., 2008). GPx1 and GPx2 are 
intracellular but GPx2 is found only in the colonic epithelium, whereas GPx1 has 
a more divergent distribution. GPx3 is found mainly in the plasma (Schwaab et 
al., 1998). GPx4 is widely expressed, but is limited by the fact that its catalytic 
power is effective only on hydroperoxides integrated in membranes (Kelner and 
Montoya, 1998). GPx5 is a secreted protein found exclusively in the epididymis 
(Rigaudiere et al., 1992). GPx6 has been identified in humans and pigs and is 
found in the olfactory epithelium (Thisse et al., 2003). GPx1 was identified in the 
cytosol, nucleus and mitochondria; GPx2 accumulates in the cytosol and 
nucleus; GPx3 is a secreted protein also found in the cytosol, whereas GPx4 is 
present in the nucleus, cytosol, mitochondria and in membrane bound form 
(Herbette et al., 2007). More recently, a new phospholipid hydroperoxide 
glutathione peroxidase (PHGPx) was described in mammals, which incorporates 
cysteine instead of selenocysteine in the conserved catalytic motif, and was 
named as NPGPx (non-selenocysteine PHGPx) (Utomo et al., 2004). NPGPx 
has a low catalytic efficiency in vitro. It is widely expressed, with prominent 
expression levels in the mammary glands (Utomo et al., 2004). 
The thioredoxins (Trxs) and GSH are important reductants in cells. Trxs 
have two cysteine residues separated by two amino acids at their catalytic site. 
Sulfhydryl groups of these cysteine residues undergo reversible oxidation 
providing reducing power to the substrate. In the case of the thioredoxin system, 
thioredoxin reductase (TrxR) reduces thioredoxin with electrons originating from 
GPx 
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NADPH, which in turn transfers reducing equivalents to numerous substrate 
proteins, including peroxiredoxin (Prx, also called thioredoxin peroxidase and 
Tpx) and ribonucleotide reductase. Trx and TrxR are localized in the 
mitochondria and cytosol. The secreted form of Trx can bind to the outer plasma 
membrane (Balcewicz-Sablinska et al., 1991).  
Being a tripeptide, GSH belongs to a family of low molecular weight 
antioxidants (Casagrande et al., 2002). The cysteine residue of GSH is 
responsible for its redox status and it non-enzymatically forms conjugates with 
reactive electrophilic compounds such as aldehydes or peroxides. The GSH and 
Trx systems were originally considered as two distinct systems, but there is a 
clear interaction between them as GSH can inactivate Trx (Casagrande et al., 
2002). Oxidation of GSH can be reversed by GSH reductase.  
1.9.2. Peroxiredoxins 
Peroxiredoxins (Prxs), are a ubiquitous group of antioxidant proteins 
(Chae et al., 1994a; Chae et al., 1994b; Mates et al., 1999) (Figure 1.8). They do 
not require any co-factors, unlike the heme-dependent catalase and the 
selenium-dependent glutathione peroxidases. Prxs are very well conserved 
across species and have been reported to be present in yeast, plants, animals, 
and in most eubacteria and archaea (Wood et al, 2003). The basic catalytic 
mechanism by which Prxs resolve peroxide in the cell is through oxidation of the 
active cysteine residue (also called the peroxidatic cysteine residue) in Prx to 
sulfenic acid. This is subsequently followed by a second step whereby the 
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sulfenic acid is recycled back to the thiol group. The second step is also what 
distinguishes the different groups of catalytic Prxs (Chae et al., 1994a; Ellis and 
Poole, 1997a; Ellis and Poole, 1997b; Choi et al., 1998). They are broadly 
classified into 3 groups: typical 2-Cys Prxs; atypical 2-Cys Prxs; and 1-Cys Prxs. 
Their importance in maintaining cellular homeostasis is underlined by their 
abundant expression in cells (Moore et al., 1991; Chae et al., 1999). Prxs have 
recently been indicated to regulate and modulate cytokine-induced hydrogen 
peroxide levels, which in turn mediate downstream signaling pathways 
responsible for cell proliferation, differentiation, and apoptosis (Hofmann et al., 
2002; Fuji and Ikeda, 2002). Prxs expression is high also in thyroid, oral and 
breast carcinomas (Yanagawa et al. 1999; Yanagawa et al. 2000; Noh et al. 
2001; Karihtala et al. 2003). Mouse models support the idea for an important role 
for Prxs in several diseases. Prx level alterations have also been noted in 
Creutzfeld-Jacob disease, Alzheimer’s disease, Pick’s and Down syndromes 
(Kim et al., 2001; Nicolls et al., 2003; Sanchez-Font et al., 2003). 
 Much still remains to be elucidated about the intricate regulation of Prxs 
expression and associated peroxidase activity. Convincing evidence for a role for 
H2O2 in cellular signaling exists as discussed, but the regulation of its 
concentration is poorly understood. As the concentrations needed for signaling 
are thought to be low, it seems unlikely that catalase could be the enzyme 
responsible for H2O2 removal. The catalytic efficiency of Prxs is weaker than that 
of GPxs or catalase, but the optimal H2O2 concentration for Prxs is relatively low, 
and for this reason, these enzymes are now considered as potential regulators of 
34 
 
endogenously produced H2O2 (Kang et al., 1998; Kang et al., 2004, Chang et al., 
2004). 
 
 
 
Figure 1.8: Major Antioxidant Enzymes, Isoforms and Subcellular 
Localization. 
 
The overall structure of the different Prxs is similar and it is the secondary 
structures that differentiate it into different isoforms. These secondary elements 
are also responsible for determining the oligomeric state in which the Prxs exists, 
which in turn defines their actions. 2-Cys Prxs seem to present as homodimers, 
but may also form heterodimers and several dimers may further group to form 
decamers (Schroder et al. 2000, Harris et al. 2001, Wood et al. 2002). Prxs 
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oligomerization is dependent on ionic strength, pH, magnesium/calcium 
concentrations and most of all, the redox state of the catalytic Cys. Peroxidase 
activity of Prxs is regulated in part by phosphorylation, cysteine oxidation, and 
limited proteolysis (Wood et al., 2003).  
1.9.2.1. Peroxiredoxin I 
Human Prx I is a 22 kDa protein expressed ubiquitously throughout the 
body (Prosperi et al. 1993, Prosperi et al. 1994, Shau et al. 1994, Pahl et al. 
1995). Earlier, it was believed that Prx I was only present in the cytosol, but 
recent investigations have indicated nuclear, mitochondrial and peroxisomal 
localization (Immenschuh et al. 2003). Serum, oxidative stresses normally induce 
Prx I, whereas H2O2 induces it in select cell types. (Ishii et al., 1993; Prosperi et 
al., 1993; Prosperi et al., 1994; Kim et al., 2000). Prx I-/- mice suffer from 
hemolytic anemia, showing the importance of Prx I in erythrocyte antioxidative 
defense (Immenschuh et al., 2003). Prx I-/- mice also develop spontaneous 
lymphomas, sarcomas and carcinomas (Neumann et al., 2003). 
1.9.2.2. Peroxiredoxin II 
Prx II s a 22 kDa protein (Harris & Naeem 1981; Kim et al., 1988; Moore et 
al., 1990; Prosperi et al., 1994; Shau et al., 1994) abundantly expressed in 
erythrocytes. It shows close resemblance to Prx I in its structure, subcellular 
location and catalytic properties (Lim et al., 1994). Prx II is anti-apoptotic. 
Exogenous expression of Prx II leads to resistance against cisplatin, irradiation, 
serum starvation, ceramide and etoposide (Zhang et al., 1997; Park et al., 2000b; 
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Chung et al., 2001). Prx II inhibits NFκB activation after TNF-α or H2O2 treatment 
(Kang et al., 1998; Kang et al., 2004). siRNA-mediated knockdown of Prx II 
makes cells more susceptible to apoptotic stimulus and Prx II-/- mice develop 
hemolytic anemia (Lee et al., 2003). 
1.9.2.3. Peroxiredoxin III 
Prx III (Tsuji et al., 1995) is a mitochondrial enzyme that plays a significant 
role in the elimination of ROS produced by aerobic metabolism.  
1.9.2.4. Peroxiredoxin IV 
Prx IV is synthesized and secreted as an inactive intracellular precursor 
(31 kDa), which subsequently becomes activated (27 kDa) upon translocation to 
its extracellular location (Okado-Matsumoto et al., 2000). The exact location and 
function of Prx IV is under debate.  It is reported to be exclusively intracellular in 
cultured rodent cells (Wong et al., 2000). Exogenous expression of Prx IV in 
these cells eliminates ROS production by the EGF or p53-mediated pathways 
(Wong et al., 2000). Prx IV is unique among the peroxiredoxins in that it exhibit 
cytokine like properties. Prx IV exposure to cells induces iNOS in a receptor-
mediated mechanism (Haridas et al., 1998). c-Jun N-terminal kinase is also 
induced by Prx IV and in turn induces proliferation in fibroblasts. Prx IV is 
anchored on the extracellular surface by heparin sulfate and its expression and 
activity is regulated by the prevailing redox status of the extracellular milieu. 
(Okado-Matsumoto et al., 2000).  
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1.9.2.5. Peroxiredoxin V 
Prx V is the smallest (17 kDa) of the Prx families. Prx V is localized in the 
cytoplasmic, nuclear and organellar milieu (Knoops et al., 1999, Seo et al., 2000, 
Zhou et al., 2000). It has the capability to bind DNA and repress RNA 
polymerase III catalyzed transcription in vitro, however the in vivo significance of 
this ability has yet to be elucidated (Kropotov et al., 1999).  Prx V is unique in that 
it is the only one of human Prxs known to act also as a peroxynitrite reductase 
(Dubuisson et al., 2004). 
1.9.2.6. Peroxiredoxin VI 
Prx VI is exclusively expressed in the cytosol (Nagase et al., 1995; Jin et 
al., 1997; Kim et al.,1997; Kim et al., 1998; Phelan et al. 1998). Prx VI belongs to 
the group of 1-Cys Prxs and is not reduced by Trx, but rather GSH (Fisher et al., 
1999, Fratelli et al., 2002, Manevich et al., 2004). It not only has peroxidase but 
also possesses phospholipase A2 activity and has been implicated in repairing 
oxidized lipids (Manevich et al., 2002). Prx VI-/- mice present a shorter life span, 
severe tissue damage and increased protein oxidation compared to normal mice 
(Wang et al., 2003). Oxidative stress in the rat lung is known to induce Prx VI 
expression (Kim et al., 2003). 
Detailed knowledge of the importance of ROS in signal amplification can 
only be achieved by a precise understanding of the intricate regulatory 
mechanisms of intracellular ROS-mediated signal transduction. The specificity of 
signaling pathways is tightly regulated by the production and elimination of 
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intracellular messengers. It can be rationalized that such regulation will be 
required for ROS, which if not eliminated can lead to deleterious effects including 
DNA damage and oxidation of proteins. Enzymatic systems exist to reverse such 
potentially deleterious effect. This reversibility of protein oxidation is very 
important in cell signaling pathways and is considered as one of the primary 
mechanisms of redox signaling (Droge, 2002). To better elucidate the various 
facets of intracellular ROS, further investigation is necessary to understand the 
mechanisms of ROS elimination. 
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CHAPTER II 
IL-4-INDUCED GENERATION OF INTRACELLULAR REACTIVE OXYGEN 
SPECIES PROMOTES IL-4-MEDIATED CELL SIGNALING 
 
 
2.1. Abstract 
IL-4 executes pleiotropic functions by activating two major intracellular 
signaling pathways: the IRS-PI3K pathway that controls the growth of target 
cells, and the Jak-STAT6 pathway that activates the transcription of genes 
involved in a variety of immune responses. Under normal physiological 
conditions, signal transduction through these pathways is limited in both 
magnitude and duration. The pathways are activated by tyrosine phosphorylation 
of IL-4 receptor-associated Jaks, receptor subunits, IRS-1/2 and STAT6.  Here, 
we show that immediately following ligand-dependent activation, the IL-4 
receptor induces an intracellular calcium flux via IRS-PI3K-PLC-γ pathway which, 
in turn, induces PKC-dependent activation of NAD(P)H oxidase (NOX5) which 
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generates reactive oxygen species (ROS). IL-4 also induces NOX1-mediated 
ROS production via the IRS-PI3K-RAC1 pathway. However, ROS are not 
required for the initiation of IL-4 receptor activation but it actively participates in 
promoting receptor activation and signal amplification.  
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2.2. Introduction 
ROS have long been recognized as toxic derivatives of diverse metabolic 
reactions. Only in the last few years it has become evident that the role of these 
oxidants is not limited to just being a byproduct but rather they have a significant 
role in the regulation of cytokine and growth factor signaling (Rhee et al., 2000). 
Redox-mediated regulation of IL-4 has not been extensively investigated. This is 
perhaps the first time when oxidant mediated amplification of IL-4 mediated 
signaling is being reported. 
Our laboratory has previously demonstrated that a non-physiologic oxidant 
pervanadate causes IL-4 receptor activation in the absence of ligand 
engagement (Haque et al., 1997).  Recent studies have shown that ROS are 
mainly produced by the NOX family enzymes, in response to cytokine or growth 
factor stimulation of cells (Rhee et al., 2000). That oxidants can facilitate or mimic 
cytokine action and ROS are generated in response to cytokine stimulation of its 
target cells have led to the hypothesis that ROS may serve as second 
messengers in the cytokine signaling cascade.  
NOX catalyzes the NADPH-dependent reduction of molecular oxygen to 
generate superoxide O2-·, which can be dismuted to generate H2O2 (Lambeth, 
2004). Flavocytochrome b558 is the catalytic core of the phagocyte NADPH 
oxidase and consists of a large glycoprotein gp91phox (or NOX-2) and a small 
protein p22phox. The other components of the NADPH oxidase are cytosolic 
proteins, namely p67phox, p47phox, p40phox and Rac (Lambeth, 2004). To 
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date, seven members of human NOX/DUOX family (NOX-1, NOX-2, NOX-3, 
NOX-4, NOX-5, DUOX-1 and DUOX-2) have been identified; the founding 
member being NOX2. The identification of NOX-1 was quickly followed by the 
cloning of NOX-3, NOX-4, and NOX-5. In parallel, two very large members of the 
NOX family were discovered, namely DUOX-1 and DUOX-2. The physiological 
functions of NOX dependent ROS generation are under investigation and require 
further characterization. The activation of NOX1, NOX2 and NOX3 requires 
specific regulatory subunits, whereas the activation of NOX5, DUOX1 and 
DUOX2 requires calcium and no regulatory subunit(s). NOX4 activity is mostly 
constitutive but can be activated by p22phox (Lambeth, 2004; Lambeth et al., 
2007).  
IL-4 activates two types of receptors. The type I receptor, comprised of the 
Jak1 bound IL-4Rα and the Jak3 bound γc (Nelms et al., 1999). Many non-
hematopoietic cells do not express γc and Jak3, where IL-4Rα associates with 
Jak2 (or TYK2) bound IL-13Rα1 to form the type II receptor (Nelms et al., 1999). 
Binding of IL-4 to IL-4Rα induces Jak1 mediated phosphorylation of multiple 
tyrosine residues in the cytoplasmic region of IL-4Rα.  These, in turn, couple and 
activate two major downstream pathways: the IRS-PI3K, which promotes the 
growth of target cells, and STAT6, which activates the transcription of IL-4-
responsive genes (Haque and Sharma, 2006; Nelms et al., 1999).  
 Here, we demonstrate that ROS are generated immediately after IL-4 
stimulation of both hematopoietic and non-hematopoietic cells, which promotes 
IL-4 receptor activation and subsequent signal transduction. Activated IL-4 
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receptor generates ROS by IRS-PI3K-mediated, calcium-dependent and -
independent activation of NOX5 and NOX1 respectively.  We also show that IL-4 
increases intracellular calcium flux, which is required for NOX5 activation.  
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2.3. Materials and Methods 
2.3.1. Cells and Reagents 
A549, 293T and NIH 3T3 cells were maintained in DMEM, supplemented 
with 10% fetal calf serum (FCS). All recombinant cytokines were purchased from 
R&D Systems. Apocynin, DPI, AG490, LY294002, wortmannin, U0126, BAPTA-
AM, U73122, Go6976 and calphostin C were obtained from Calbiochem. 
Nifedipine and heparin were purchased from Sigma. Anti-phospho 
(Tyrosine641)-STAT6 and anti-phospho-tyrosine PY100 were purchased from 
Cell Signaling Technology, and anti-V5 was from Invitrogen. Anti-STAT6, anti-β-
actin, anti-FLAG and anti-goat HRP were obtained from Santa Cruz 
Biotechnology.  
2.3.2. Intracellular ROS Assays 
ROS were measured fluorimetrically using CM-H2DCFDA probe ( Myhre 
et al., 2003; Choi et al., 2005). Briefly, adherent cells were washed twice with 
Hank’s balanced salt solution (HBSS), incubated with 5 µM CM-H2DCFDA in 
HBSS for 10 min at 37°C in 5% CO2, washed and stimulated with indicated 
cytokine at 37°C under a Leica DMIRB inverted microscope (Leica Microsystems) 
equipped with a Retiga EXi Cooled CCD Camera (Q Imaging, Burnby), with a 
Ex490nm and standard fluorescein filter. Images were taken at every 10 sec, and 
fluorescence signals were quantified using Image Pro Plus Software (Media 
Cybernatics).  Each value in relative fluorescence units (RFU) represents mean ± 
SE of three independent measurements; each measurement represents the 
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mean fluorescence signals of five equivalent fields (approximately same number 
of cells). To measure ROS for longer 
time periods (>5 min), cells were loaded with CM-H2DCFDA, trypsinized, 
resuspended in HBSS, and changes in fluorescence signals were measured 
using flow cytometry (FACScan, Beckton-Dickinson).  ROS produced by non-
adherent cells were measured using Victor2 Wallace Mutichannel Reader (Perkin 
Elmer) using Ex495nm and Em535nm filters.  
2.3.3. Electrophoretic Mobility Shift, Supershift and Luciferase Assays 
EMSA was performed using 10 µg proteins of whole cell extracts and 0.2 
ng of 32P-labeled high-affinity STAT6-specific probe (Haque et al., 2000). Cell 
extracts were incubated with 2 µg of normal rabbit IgG or anti-STAT6 antibody 
prior to incubation with 0.2 ng of radiolabeled oligonucleotide duplex for 20 min 
for super-shift assay, or with 10 ng or 50 ng of unlabeled wild-type or mutant 
oligonucleotide duplex for competition assay. The sequences for the sense 
strand of the oligonucleotide are: 5’-GATCGCTCTTCTTCCCAGGAACTCA-ATG-
3’ (wild-type) and 5’-GATCG-CTCTTCTTCCCAGGGGCTCAATG-3’ (mutant) 
with the conserved N6-GAS sequence underlined (Haque et al., 2000), and the 
mutated nucleotides italicized. The DNA-protein complexes were resolved on 
native 6% polyacrylamide gels, dried and visualized after incubation at -80oC. 
Luciferase assay was performed using the Dual Luciferase Assay Kit (Promega) 
as per the manufacturer’s instructions.  
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2.3.4. Cloning, Site-directed Mutagenesis and Plasmid Constructs 
Murine IL-4Rα cDNA was isolated from a NIH3T3 cell-derived cDNA 
library by PCR, and cloned in pcDNA3.1/V5-HisA (Invitrogen). The constructs for 
p22phox (wild-type and P156Q mutant), NOX1, NOXA1, NOXO1, NOX4 and 
NOX5L and p22phox shRNA (specific and scramble) are described (Kawahara et 
al., 2005). The wild-type (WT) and mutant (C174S) PTEN constructs were 
obtained from Dr. Charis Eng, and wild-type (WT) and mutant (T17N) RAC1 
constructs from Dr. Olga Stenina. All point mutants were generated using Quick 
Change XL Site-directed Mutagenesis Kit (Stratagene) following the 
manufacturer’s instructions. DNA oligonucleotides encoding shRNA sequences 
with loop sequence (5’-TTC- AAGAGA-3’) were cloned into pSuper-Neo 
(OligoEngine) according to the manufacturer’s instructions. The specific target 
sense sequences were: 5’-GAATTAGGCAAAGTGGGTT-3’ for NOX1, 5’-
AAGAGCGATTCTTTGCCCTAT-3’ for NOX5L, 5’-CGGGAAGACAAGTTCA-
TGTACTT-3’ for PTEN, 5’-GAACAACCGGCTCTTCGT-3’ for PLCγ1, and 5’-
AATCCTGA-CTTCCGAGAA-3’ for PLCγ2. The scramble versions of the target 
sequences were generated using siRNA Wizard (InVivogen), and cloned in 
pSuper-Neo vector (OligoEngine). All constructs were verified by nucleotide 
sequencing. 
 
 
 
47 
 
2.3.5. Transfection  
A549 and 293T cells were transfected using Lipofectamine 2000 
(Invitrogen) and calcium phosphate co-precipitation respectively (Haque et al., 
2000) with transfection efficiencies of 70-80% and ~90% respectively.  
2.3.6. RT-PCR  
For determination of mRNA levels, 1.0 µg of total RNA was used for first-
strand cDNA synthesis according to the manufacturer’s protocol (Invitrogen). 
One-tenth of cDNA was used as a template for 35 cycles of PCR using specific 
primer sets listed in Table I.  
2.3.7. RAC1 Activation Assay  
A549 cells were treated with 20 µM LY294002 or DMSO (vehicle) for 2 hr 
after which the cells were treated with IL-4 (20 ng/ml) for 5 min, or left untreated. 
Cell lysates were used to detect active RAC1 using the RAC1/Cdc42 Activation 
Assay Kit (Millipore) following the manufacturer’s instructions. 
2.3.8. Measurement of Cytoplasmic Calcium Flux  
For measurement of cytoplasmic calcium flux, cells were incubated with 
the calcium indicator dye, Fluo4-AM (1 µM), for 30 min in complete DMEM, 
according to the manufacturer’s instructions (Molecular Probes). Before 
measurement of fluorescence signals, cells were washed twice with phenol red-
free DMEM, and incubated for another 15 min for complete hydrolysis of 
intracellular AM-esters. Images of cells were taken both before and after IL-4 
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stimulation, at every 2 sec for 6 min at 37ºC. Images were obtained with Leica 
SP-2 AOBS confocal microscope (Leica-Microsystems) using an HCX PL APO 
40X/1.25 NA oil immersion objective lens (Murata et al., 2004), with minor 
modifications. Fluo4 was excited with the 488 nm line of an argon laser, and its 
fluorescence emission was recorded between 500-550 nm using the built-in 
spectrophotomer. Illumination intensity was kept to a minimum (50 µW) to avoid 
phototoxicity, and the pinhole was set to two Airy units. Fluorescence signals 
were quantified using Leica confocal software (Leica-Microsystems).  
2.3.9. Statistical and Densitometric Analyses 
All experiments were performed at least three times. Statistical differences 
between different groups were determined using paired Student’s t-test. EMSA 
and immunoblot signals were quantified using ImageQuant (Molecular 
Dynamics). 
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Table I: PCR Primer Sets with Expected Sizes of the PCR Products. 
Gene 
Name 
 
Expected 
Size (bp) 
 
Primer Sequences 
 
Expected 
Size (bp) 
 
Primer Sequences 
 
   
A: Human Cells 
 
  
B. Mouse Cells 
NOX1 235 Forward: 5’-GGAGCAGGAATTGGGGTCAC3’ 
Reverse: 5’-TTGCTGTCCCATCCGGTGAG-3’ 
 
431 Forward: 5′-TGAACAACAGCACTCACCAATGCC-3′ 
Reverse: 5′-TCATTGTCCCACATTGGTCTCCCA-3′ 
 
NOX2 549 Forward: 5’-TTGCTGTCCCATCCGGTGAG-3’ 
Reverse: 5’-GCCAGACTCAGAGTTGGAGATGCT-
3’ 
 
301 Forward: 5′-TGGCTGTGATAAGCAGGAGTTCCA-3′ 
Reverse: 5′-TGTTCCTTTCCTGCATCTGGGTCT-3′ 
 
NOX3 457 Forward: 5’-GGATCGGAGTCACTCCCTTCGCTG-
3’ 
Reverse: 5’-ATGAACACCTCTGGGGTCAGCTGA-
3’ 
 
492 Forward: 5′-TTGTGGCACACTTGTTCAACCTGG-3′ 
Reverse: 5′-TCACACGCATACAAGACCACAGGA-3′ 
 
NOX4 285 Forward: 5’-CTCAGCGGAATCAATCAGCTGTG-3’ 
Reverse: 5’-AGAGGAACACGACAATCAGCCTTA-
3’ 
 
521 Forward: 5′-TCATGGATCTTTGCCTCGAGGGTT-3′ 
Reverse: 5’-AGTGACTCCTCAAATGGGCTTCCA-3′ 
 
NOX5 238 Forward: 5’-ATCAAGCGGCCCCCTTTTTTTCAC-3’ 
Reverse: 5’-CTCATTGTCACACTCCTCGACAGC-
3’ 
 
  
NOX5L 557 Forward: 5’-CGCCATCTCGCTGCCTGACG-3’ 
Reverse: 
5’CCGCCTGAGCCTGGAGTACAAAGTTC-3’ 
 
  
DUOX1 144 Forward: 5’-GTATGTCTTTGCCTCCCACC-3’ 
Reverse: 5’-GAAGAAGATGTGGAAACGGG-3’ 
 
760 Forward: 5′-CACCATTGGGACCCTTTGCTGTTT-3′ 
Reverse: 5′-AGCCTTCATGAAGACCACCAGGA-3’ 
 
DUOX2 121 Forward: 5’-ATGACCTGGATGAGAATGGC-3’ 
Reverse: 5’-CATAGACTCCACCACCTCGG-3’ 
 
590 Forward: 5′-AACCACCTATGTGGGCATCATCCT-3′ 
Reverse: 5′-AGCTGCCATGGATGATGATCTGGA-3′ 
 
PTEN 176 Forward: 5’-CTGCAATTAAATTTGGCGCT-3’ 
Reverse: 5’-TCCTGCAGAAAGACTTGAAGG-3’ 
 
  
PLCγ1 186 Forward: 5’-CCAGGTCAACTACCGGGTC-3’ 
Reverse: 5’-GGAACTCAGGAAGGGACACTC-3’ 
 
  
PLCγ2 189 Forward: 5’-TCCACCACGGTCAATGTAGAT-3’ 
Reverse: 5’-TGGGCGGATTTCTTTTATTTCCA-3’ 
 
  
β-ACTIN 209 Forward: 5’-CATGTACGTTGCTATCCAGGC-3’ 
Reverse: 5’-CTCCTTAATGTCACGCACGAT-3’ 
 
426 Forward: 5′-AAGGCCAACCGTGAAAAGAGACC-3′ 
Reverse: 5′-ACCGCTCGTTGCCAATAGTGATGA-3′ 
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2.4. Results 
2.4.1. IL-4 Generates ROS that Promote Intracellular Signal Transduction 
We have previously demonstrated that IL-4 receptor-associated PTP 
activity is susceptible to inactivation by PV, which is an exogenous oxidant 
(Haque et al., 1997). Here, we demonstrate for the first time, that IL-4 stimulation 
of A549 cells generated endogenous oxidants, ROS, within 10 sec (Figures 2.1 & 
2.2A) and reached a peak at ~15 min; declining thereafter (Figure 2.2B). 
Although the fluorescence probe, CM-DCFH2-DA used for ROS measurement, 
can also detect reactive nitrogen species (RNS), pretreatment of cells with an 
inhibitor of nitric oxide synthase, L-NAME (Kubes et al., 1991), did not reduce IL-
4-generated fluorescence intensity, indicating that in response to IL-4, A549 cells 
did not generate RNS (Figure 2.3A). To examine if NOX family members were 
involved in IL-4-induced ROS production, ROS were measured in A549 cells 
pretreated with diphenylene iodonuim (DPI), an inhibitor of flavoprotein (Cross 
and Jones, 1986), and apocynin, an inhibitor of NOX activity (Fu et al., 2006). 
Both the inhibitors completely blocked IL-4-induced ROS production (Figure 
2.3A) suggesting that NOX-family enzymes were involved in this process. 
Importantly, these inhibitors also significantly reduced IL-4-dependent STAT6 
activation as measured by EMSA (Figure 2.3B), as well as subsequent gene 
expression, as determined by luciferase assay (Figure 2.4). Similar observations 
were made in mouse primary splenocytes (Figures 2.5A & B) and in other cells of 
both human and mouse origins (data not shown). The specificity of DNA-protein 
complexes in EMSA was confirmed by competition with an excess of unlabeled 
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DNA probe, and by super-shift using a STAT6-specific antibody (data not 
shown). Collectively, these data suggest that IL-4 induces ROS production in all 
cell types examined, and ROS induce amplification but not initiation of IL-4 
signaling. 
2.4.2. IL-4 Activates NOX through the IRS-PI3K Pathway 
To identify the biochemical pathways through which ROS were generated 
in IL-4-stimulated cells, we used A549 as a model cell line. Binding of IL-4 to its 
receptor activates the IRS-PI3K, STAT6 and RAS-MAPK pathways in some cells 
(Haque and Sharma, 2006; Nelms et al., 1999). Pretreatment with Jak inhibitor, 
AG490 (Meydan et al., 1996), or PI3K inhibitors, LY294002 and wortmannin 
(Fukuchi et al., 2000) but not MEK1 inhibitor, U0126 (DeSilva et al., 1998), 
completely blocked ROS production by IL-4, suggesting that Jak and PI3K 
activities were required for IL-4-induced ROS production (Figure 2.6A). AG490, 
LY294002 and wortmannin, but not U0126, also significantly inhibited IL-4-
dependent STAT6 activation (Figure 2.6B), further suggesting that ROS promote 
IL-4-dependent signal transduction. 
 To confirm the roles of PI3K and STAT6 in IL-4-induced ROS generation, 
we undertook the following approach. IL-4 signals in A549 cells through the type 
II receptor (Haque and Sharma, 2006; Nelms et al., 1999). Since the binding of 
IL-4 to its primary receptor, IL-4Rα, is species-specific (Ohara and Paul, 1987), 
A549 (human) cells did not respond to murine IL-4 (data not shown). IL-13Rα1, 
which serves as a secondary receptor chain in type II IL-4 receptor, in A549 cells 
does not exhibit species specificity (Nelms et al., 1999). We isolated cDNA of 
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murine IL-4Rα, confirmed its functionality (Figure 2.7), and generated a mutant 
receptor (Tyr500Phe) which is deficient in activating the IRS-PI3K pathway 
(Nelms et al., 1999). When expressed in A549 cells, the wild-type murine IL-4Rα 
efficiently supported murine IL-4-induced ROS generation, whereas the mutant 
IL-4Rα (Tyr500Phe) failed to do so (Figure 2.8), confirming that IRS-PI3K 
couples the IL-4 receptor to the ROS-generating system. In addition, inhibition of 
PTEN expression by shRNA (Figure 2.9, upper panel) significantly enhanced IL-
4-induced ROS production (Figure 2.10), and subsequent STAT6 activation 
(Figure 2.9, lower panel) in A549 cells. Further, overexpression of wild-type, but 
not a catalytically inactive mutant PTEN (C124S) (Myers et al., 1997), 
significantly inhibited IL-4-induced ROS generation in A549 cells (Figure 2.11). 
Taken together, these results confirm the requirement of PI3K activity in IL-4-
induced ROS generation and downstream signaling. 
  Murine IL-4Rα did not support the activation of human STAT6, in 293T 
cells (Figure 2.7), suggesting that IL-4Rα-STAT6 interaction is also species-
specific. Consistent with this, in response to murine IL-4 treatment, A549 cells 
expressing the murine IL-4Rα did not activate endogenous (human) STAT6 but 
efficiently supported ROS generation (Figure 2.8).  Moreover, cycloheximide did 
not alter IL-4-induced ROS generation in A549 and other cells (data not shown). 
Taken together, these data clearly indicate that IL-4Rα-mediated ROS 
generation does not require either STAT6 activation or new protein synthesis.  
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2.4.3. IL-4 Activates NOX1 and NOX5 
The next question was which of the NOX-family members were involved in 
IL-4-induced ROS production? We found that NOX1, NOX4 and NOX5L (long 
form) were predominantly expressed in A549 cells (Figures 2.12 and 2.13). 
Overexpression of NOX1 and NOX5L but not NOX4 in A549 cells significantly 
increased IL-4-induced ROS generation (Figure 2.14A) as well as STAT6 
activation (Figure 2.14B). Further, inhibition of NOX1 expression by shRNA 
(Figure 2.20) significantly compromised IL-4-induced ROS generation (Figure 
2.15), and STAT6 activation (Figure 2.21) in A549 cells. NOX1 activation 
requires its regulatory subunits, p22phox, NOXA1, NOXO1 and RAC1 (Lambeth 
et al., 2007). We found that IL-4-induced ROS generation in A549 cells was 
significantly increased by overexpression of p22phox (Figure 2.16) and markedly 
compromised by either overexpression of a dominant-negative mutant p22phox 
(P156Q) (Kawahara et al., 2005) or shRNA-mediated inhibition of p22phox 
expression (Figure 2.16). In addition, reconstitution of NOX1 complex in A549 
cells by overexpression of NOX1, NOXO1 and NOXA1 significantly increased IL-
4-induced ROS generation (Figure 2.17). Moreover, IL-4-induced ROS 
generation was inhibited by overexpression of a dominant negative mutant (N17) 
RAC1 (Cool et al., 1998) (Figure 2.18). Further, IL-4 stimulation of A549 cells 
significantly increased RAC1 activation, which was markedly compromised by 
inhibition of PI3K activity (Figure 2.19). Collectively, these data demonstrate that 
IL-4 activates NOX1 complex through the IRS-PI3K-RAC1 pathway.  
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 Here, we also demonstrated the involvement of NOX5 in IL-4-induced ROS 
production and STAT6 activation by overexpression (Figures 2.14A & B) and 
silencing of NOX5 gene, in A549 cells (Figures 2.15; 2.20; 2.21). Since NOX5L 
activation requires binding of calcium to its EF hands (Banfi et al., 2004; Lambeth 
et al., 2007), we examined if IL-4-induced ROS generation was dependent on 
intracellular calcium flux. Pretreatment of A549 cells with BAPTA-AM, a general 
calcium chelator (Tsien, 1980), or heparin, an inhibitor of IP3-receptor-mediated 
calcium flux (Seuwen and Boddeke, 1995) but not nifedipine, a blocker of L-
channel-mediated calcium flux (Reid et al., 1997), significantly inhibited IL-4-
induced ROS generation (Figure 2.22A) and STAT6 activation (Figure 
2.22B). Therefore, it was important to determine if IL-4 stimulation of cells 
increased cytoplasmic calcium flux. Using Fluo-4AM (Murata et al., 2004), an 
increase in cytoplasmic calcium flux was detected by confocal microscopy within 
5 sec of IL-4 stimulation of A549 cells, which continued to increase for ~180 sec, 
and reached a plateau thereafter (Figures 2.23 & 2.24). The kinetics of this 
calcium flux correlated with that of IL-4-induced ROS generation (Figure 2.2A). 
Next, pretreatment of A549 cells with PLC-γ inhibitor, U73122 (Stam et al., 1998), 
or inhibitors of diacylglycerol (DAG)-dependent PKC activity, calphostin C (Jarvis 
et al., 1994) and Go6976 (Gschwendt et al., 1996), significantly inhibited IL-4-
induced ROS generation (Figure 2.25). Further, shRNA-mediated inhibition of 
PLCγ1 and PLCγ2 expression significantly reduced IL-4-induced ROS production 
(Figure 2.26A), and subsequent STAT6 activation (Figure 2.26B), in A549 cells. 
Collectively, these results demonstrate that activated IL-4 receptor induces an 
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intracellular calcium flux via IRS-PI3K-PLC-γ pathway which likely induces DAG- 
and calcium-dependent PKC-mediated activation of NOX5L to generate ROS. 
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Figure 2.1: IL-4 Generates ROS in A549 cells.  
Cells were loaded with 5 µM CM-DCFH-DA, stimulated with IL-4 (20 ng/ml) under 
fluorescence microscope and pictures taken.  
 
 
 
Figure 2.2: Quantitation of IL-4 Induced ROS in A549 cells. 
(A) ROS generation is rapid in the early phases of IL-4 action. CM-DCFH-DA loaded 
A549 cells were stimulated with IL-4 (20 ng/ml) and fluorescence intensities were 
quantified. Values in relative fluorescence units (RFU) represent mean ± SE, (n=3). 
(B) ROS Level Peaks at ~15 min after IL-4 stimulation of A549 Cells. ROS were 
measured by flow cytometry after IL-4 stimulation of cells for indicated lengths of 
time. The values in RFU are plotted as mean ± SE (n=3). 
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Figure 2.3: IL-4 Generates ROS by NOX Activation.  
(A) A549 cells were pretreated for 2 hr with apocynin (500 µM), DPI (10 µM) or L-
NAME (50 µM), and ROS were measured following IL-4 stimulation. RFU represent 
mean ± SE, (n=3) (** indicates P< 0.01).  
(B) Blockade of ROS generation inhibits IL-4-dependent STAT6 activation. A549 
cells were pretreated with apocynin, DPI or DMSO as described above, and treated 
with IL-4 (20 ng/ml) for indicated times. Cell extracts were subjected to EMSA and 
relative signal intensities (RSI) were quantified using ImageQuant software. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4. Blockade of ROS Generation Inhibits IL-4-dependent Gene 
Expression.  
A549 cells were transfected with 4.0 µg DNA of STAT6-responsive luciferase 
construct. After 48 hr, cells were pretreated with 500 µM apocynin (or DMSO) for 2 
hr, stimulated with IL-4 (20 ng/ml) for indicated periods, and luciferase activity 
measured. Luciferase activities in arbitrary units (AU) are plotted as mean ± SE, 
(n=3) (** = P < 0.01; NS = not significant).  
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Figure 2.5: IL-4-dependent ROS Generation Requires Jak and PI3K Activities. 
 (A) A549 cells were pretreated with AG490 (50 µM for 6 hr), LY294002 (20 µM for 2 
hr), wortmannin (10 nM for 2 hr), U0126 (25 µM for 2 hr), or DMSO, and IL-4-
induced ROS production measured. RFU are plotted as mean ± SE, (n=3).  
(B) Blockade of Jak or PI3K activity inhibits IL-4-induced STAT6 activation. A549 
cells were pretreated with the inhibitors described above, and stimulated with IL-4 
(20 ng/ml) for 5 min. Cell extracts were subjected to EMSA, and RSI quantified.  
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Figure 2.6: IL-4 Generates ROS by NOX Activation in Mouse Primary 
Splenocytes. 
(A) Splenocytes were pretreated for 2 hr with apocynin (500 µM) and ROS 
measured following IL-4 stimulation. RFU represent mean ± SE, (n=3) (** indicates 
P< 0.01). 
(B) Blockade of NOX activity inhibits IL-4-dependent STAT6 activation in mouse 
primary splenocytes. Cells were pretreated with apocynin (500 µM) for 2 hr, and 
treated with IL-4 (20 ng/ml) for indicated times. Cell extracts were subjected to 
EMSA and RSI quantified. 
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Figure 2.7: Murine IL-4Rα Activates Murine but not Human STAT6  
293T cells were transfected with 2.0 µg of murine IL-4Rα (lanes 3, 5 and 7) or vector 
(lanes 4 and 6) along with (i) 2.0 µg of human STAT6, 2.0 µg of γc and 2.0 µg of 
Jak3 (lanes 3 and 4), (ii) 2.0 µg of murine STAT6, 2.0 µg of γc and 2.0 µg of Jak3 
(lanes 5 and 6) or (iii) only 2.0 µg murine STAT6 (lane 7). For controls, cells were 
transfected with (iv) 2.0 µg of human IL-9Rα, 2.0 µg of human STAT5A, 2.0 µg of 
human γc and 2.0 µg of Jak3 (lane 1), or (v) with 2.0 µg of human STAT6 (lane 2). 
After 48 hr, cells were stimulated for 30 min with human IL-4 (20 mg/ml), murine IL-4 
(20 ng/ml) or human IL-9 (10 ng/ml) as indicated. Cell extracts were subjected to 
EMSA using radiolabeled probes specific for STAT5 (lane 1) or STAT6 (lanes 2-7).  
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Figure 2.8:  PI3K Activation is required for IL-4-induced ROS Generation.  
A549 cells were transfected with 1.0 µg of murine wild-type IL-4Rα, mutant IL-4Rα  
(Y500F), or vector.  After 48 hr, IL-4-generated ROS were measured and RFU 
plotted as mean ± SE, (n=3) (** indicates P < 0.01) 
 
 
 
 
 
 
 
 
Figure 2.9: Inhibition of PTEN Expression Increases IL-4-dependent STAT6 
Activation. 
A549 cells were transfected with 4.0 µg of shRNA (or scrambled) construct for 
PTEN. After 48 hr, total RNA was isolated and steady-state PTEN mRNA levels 
determined by RT-PCR (upper panel). Alternatively, 48 hr post-transfection, cells 
were stimulated with IL-4 (20 ng/ml) for 5 min. Cell extracts were subjected to EMSA 
and RSI quantified (bottom panel). 
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Figure 2.10: Inhibition of PTEN expression increases IL-4-induced ROS 
generation.  
A549 cells were transfected with 4.0 µg of shRNA (or scrambled) construct for 
PTEN. After 48 hr, IL-4 generated ROS were measured and RFU plotted as mean ± 
SE, (n=3) (** indicates P < 0.01).  
 
 
 
 
 
 
 
                                                                                                                                       
Figure 2.11: PTEN Over-expression Significantly Inhibits IL-4-dependent ROS 
Generation 
A549 cells were transfected with 3.0 µg of vector, wild-type or mutant PTEN  
(C174S) along with 1.0 µg of murine IL-4Rα plasmid . After 48 hr, murine IL-4-
generated ROS were measured and RFU plotted as mean ± SE, (n=3) (** indicates 
P < 0.01).  
63 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.12: Different NOX Genes are Expressed in A549 cells.  
Total RNA from A549 cells was used for RT-PCR using NOX-specific primers (upper 
panel), or for β-actin (lower panel). The expected sizes (bp) of PCR products are 
indicated below, and non-specific products are indicated by asterisks. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 2.13: A549 cells Express NOX5L.  
The expression of NOX2 and NOX5L (and β-actin as control) was checked using 
RT-PCR. The expected sizes (bp) of the individual products are indicated. 
 
64 
 
 
 
 
Figure 2.14: NOX1 and NOX5 are Involved in IL-4-dependent ROS Production 
(A) Overexpression of NOX1 and NOX5, but not NOX4, increases IL-4-dependent 
ROS generation. A549 cells were transfected with 1.0 µg of murine IL-4Rα along 
with 3.0 µg of NOX1, NOX4 and NOX5 (or appropriate vector controls) plasmid. 
After 48 hr, murine IL-4-generated ROS were measured and RFU plotted as mean ± 
SE, (n=3) (* = P < 0.05; ** = P < 0.01).  
(B) Overexpression of NOX1 and NOX5, but not NOX4, increases IL-4-dependent 
STAT6 activation. A549 cells were transfected with 1.0 µg of murine IL-4Rα along 
with 3.0 µg of NOX1, NOX4 and NOX5 (or appropriate vector control) plasmid. After 
48 hr, cell extracts were subjected to EMSA and RSI quantified. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.15: Inhibition of NOX1 and NOX5 Expression Reduces IL-4-dependent 
ROS Generation.  
A549 cells were transfected with 4.0 µg of shRNA constructs for NOX1, NOX5 or 
their scrambled versions. After 48 hr, IL-4 generated ROS were measured and RFU 
plotted as mean ± SE, (n=3). (* = P < 0.05).  
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Figure 2.16: p22phox Activity Regulates IL-4-induced ROS Production.   
A549 cells were transfected with 1.0 µg of murine IL-4Rα  along with 3.0 µg of 
wild-   type p22phox, mutant p22phox (P156Q), specific shRNA (N or C forms) or 
scrambled controls/ corresponding vector plasmids. After 48 hr, murine IL-4-
generated ROS were measured and RFU plotted as mean ± SE, (n=3) (* = P < 
0.05; ** = P < 0.01). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.17: NOXO1 and NOXA1 are Involved in IL-4-mediated ROS 
Production  
Overexpression of NOXO1 or NOXA1 increases IL-4-dependent NOX1-mediated 
ROS production. A549 cells were transfected with 1.0 µg of murine IL-4Rα  along 
with NOX1, NOXO1 and NOXA1, singly or in combination (total 3.0 µg plasmid). 
After 48 hr, murine IL-4-generated ROS were measured and in RFU plotted as 
mean ± SE, (n=3) (** = P < 0.01). 
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2.18: RAC1 is Involved in IL-4-induced ROS Production.  
A549 cells were transfected with 1.0 µg of murine IL-4Rα  along with 3.0 µg of wild-
type or dominant-negative mutant (N17) RAC1 constructs. After 48 hr, murine IL-4-
generated ROS were measured and RFU plotted as mean ± SE, (n=3) (* = P < 
0.05).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.19: PI3K Activity is required for IL-4-induced RAC1 Activation.  
A549 cells were treated with 20 µM LY294002 for 2 hr after which the cells were 
treated with IL-4 (20 ng/ml) for 5 min, or left untreated. Cell lysates were analyzed 
for detection of active (upper panel) or total (lower panel) RAC1, by Western 
analyses.  
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Figure 2.20: Steady-state Levels of NOX1 and NOX5L mRNAs after shRNA-
mediated Inhibition.    
A549 cells were transfected with 4.0 µg of shRNA constructs for NOX1, NOX5 or 
their scrambled versions. After 48 hr, steady-state levels of NOX1 and NOX5L 
mRNAs were determined by RT-PCR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.21: Inhibition of NOX1 and NOX5 Expression Reduces IL-4-dependent 
STAT6 activation.  
A549 cells were transfected as in (Figure 2.20). After 48 hr, cells were stimulated with 
murine IL-4 (20 ng/ml) for 5 min. Cell extracts were subjected to EMSA and RSI 
quantified. 
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Figure 2.22: IL-4 Induces Calcium Flux which Increases ROS Production. 
(A) IL-4-dependent ROS generation is inhibited by blocking IP3-receptor-mediated 
calcium release. A549 cells were treated for 2 hr with BAPTA-AM (30 µM), heparin (1 
µM), nifedipine (0.1 nM) or DMSO, and IL-4-generated ROS measured and RFU 
plotted as mean ± SE, (n=3) (** = P < 0.01).  
(B) Inhibitors of IP3-receptor-mediated calcium release compromise IL-4-dependent 
STAT6 activation. A549 cells were pretreated as in (A), treated with IL-4 (20 ng/ml) 
for 5 min. Cell extracts were subjected to EMSA and RSI quantified. 
 
 
 
 
 
 
 
 
 
 
Figure 2.23: Quantitation of IL-4-stimulated Cytoplasmic Calcium Flux. 
A549 cells were loaded with 1 µM Fluo4-AM and changes in cytoplasmic calcium 
levels measured using live-cell confocal microscopy. The arrow indicates the time 
when the medium was replaced by fresh medium containing 20 ng/ml of IL-4 or 1 µM 
of ionomycin (as positive control). The experiment was performed five times and data 
from one representative experiment shown.   
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Figure 2.24: IL-4-stimulation Increases Cytoplasmic Calcium Flux. 
A549 cells treated as above (Figure 2.23) and confocal microscopic pictures taken. 
The experiment was performed five times and data from one representative 
experiment is shown.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.25: IL-4-mediated ROS Generation Is Dependent on PLC-γ and DAG-
dependent PKC Activities.  
A549 cells were pretreated for 2 hr with U73122 (2 µM), calphostin C (10 µM), 
Go6976 (1 µM) or DMSO, and IL-4-induced ROS production measured. RFU are 
plotted as mean ± SE, (n=3). (* = P < 0.05; ** = P < 0.01). 
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Figure 2.26: Inhibition of PLC-γ1 or PLC-γ2 Expression by shRNA Reduces IL-4-
dependent ROS Generation and STAT6 Activation.  
(A) A549 cells were transfected with 4.0 µg of shRNA or scrambled constructs for 
PLC-γ1 or PLC-γ2. After 48 hr, IL-4 generated ROS were measured and RFU plotted 
as mean ± SE, (n=3) (* = P < 0.05; ** = P < 0.01).  
(B) Inhibition of PLC-γ1 or PLC-γ2 expression increases IL-4-dependent STAT6 
activation. A549 cells were transfected as in (A). After 48 hr, PLC-γ1 and PLC-γ2 
transcript levels were determined by RT-PCR (upper panel). Alternatively, 48 hr post-
transfection, cells were stimulated with IL-4 for 5 min. Cell extracts were subjected to 
EMSA and RSI quantified.  
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      2.5. Discussion 
In this study we have demonstrated, for the first time that immediately 
following IL-4 engagement the activated IL-4 receptor produced ROS that, in turn, 
increased the magnitude of receptor activation and consequent signal 
transduction, in the absence of de novo protein synthesis.  
We identified biochemical pathways that coupled an activated IL-4 
receptor to ROS producing enzymes NOX1 and NOX5. The mechanism of 
activation has been best characterized for NOX2, the founding member of the 
family. In response to appropriate stimuli, a membrane-bound flavocytochrome 
(b558) composed of NOX2 (gp91phox) and p22phox forms an activation complex 
by recruiting at least three cytoplasmic proteins which includes p67phox, 
p47phox, (p40phox in some cases) and RAC2 (Lambeth, 2004; Lambeth et al., 
2007).  NOX1 also forms an activation complex with p22phox, RAC1, NOXO1 
(p67phox homolog) and NOXA1 (p47phox homolog) (Lambeth, 2004; Lambeth et 
al., 2007). Inhibition of p22phox and RAC1 activities by dominant-negative 
mutants, or RNAi-mediated silencing of p22phox significantly reduced IL-4-
mediated ROS generation. On the other hand, ROS generation was significantly 
increased by overexpression of NOXO1, NOXA1, p22phox and RAC1, 
suggesting the involvement of these components in IL-4-mediated NOX1 
activation. This corroborates an earlier report that demonstrated IL-4-dependent 
RAC1 activation in human keratinocytes (Wery-Zennaro et al., 2000).  
 NOX5 is a calcium-dependent enzyme that does not require any 
regulatory subunits (Banfi et al., 2001; Banfi et al., 2004). Both overexpression 
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and RNAi-mediated gene silencing data suggested the involvement of NOX5L in 
IL-4-dependent ROS generation. Further, IL-4-dependent ROS generation was 
significantly compromised by inhibitors of cytoplasmic calcium flux, suggesting 
that calcium flux is required for NOX5 activation by IL-4. However, it was not 
known if IL-4 induces calcium flux. Using the calcium indicator dye, Fura-2, we 
could not detect IL-4-induced calcium flux (data not shown). An earlier study also 
failed to detect IL-4-dependent calcium flux (Ho et al, 1994). Using Fluo-4AM, 
whose fluorescence intensity increases >100-fold upon calcium binding (Harkins 
et al., 1993), we demonstrated, for the first time, that IL-4 induced an immediate 
cytoplasmic calcium flux in A549 cells. Interestingly, IL-4-dependent ROS 
generation was compromised by inhibitors of DAG-dependent PKCs. A recent 
study has shown that activation of NOX5 is regulated by an unidentified PKC-
mediated phosphorylation of specific serine /threonine residues (Jagnandan et 
al., 2007). A number of previous studies have focused on DAG- and calcium-
independent PKC-mediated regulation of IL-4 signaling (Duran et al., 2004; Ho et 
al., 1994; Ikizawa et al., 1994). Our results suggest a role for classical PKCs 
which depend on both DAG and calcium, in IL-4-mediated cell signaling. 
Moreover, IL-4-dependent ROS generation was compromised by PLC-
γ inhibition. Two studies have demonstrated the role for PLC-γ1 in IL-4 signaling 
(Ikizawa et al., 1994; Ikizawa and Yanagihara, 2000), whereas another report 
has implicated  a role of PC-PLC, but not PLC-γ, in IL-4 signaling (Zamorano et 
al., 2003). This may be due to the use of mouse cells in the latter study, which do 
not express NOX5 (Banfi et al., 2001).  
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In summary, we have shown that activated IL-4 receptor generated ROS 
in an IRS-PI3K-mediated, calcium-dependent and -independent activation of 
NOX5L and NOX1, respectively. We also demonstrated that IL-4 increased 
intracellular calcium flux, which is required for NOX5L activation.  
The next logical goal was to understand the biochemical basis of ROS-
mediated amplification of IL-4 signaling. More specifically, it will be important to 
identify the PTP, which negatively regulate IL-4 signaling, and to investigate if 
ROS generated by activated IL-4 receptor oxidatively inactivates the PTP activity. 
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CHAPTER III 
IL-4-STIMULATION GENERATES ROS, WHICH CATALYTICALLY 
INACTIVATES PTP1B AND UPREGULATES RECEPTOR ACTIVATION 
 
 
 
3.1. Abstract 
The physiologic control of cytokine receptor activation is primarily 
mediated by reciprocal activation of receptor-associated PTKs and PTPs. We 
have shown in chapter II that following ligand-dependent activation, IL-4 receptor 
induces an intracellular calcium flux via IRS-PI3K-PLC-γ pathway which, in turn, 
induces PKC-dependent activation of NOX5 that generates reactive oxygen 
species (ROS). Given our earlier findings, it was imperative to understand the 
biochemical basis of ROS-mediated IL-4 signal amplification. More specifically, it 
was important to identify the PTP and to investigate if ROS generated by 
activated IL-4 receptor oxidatively inactivate the IL-4 receptor-associated PTP 
activity. We show here that ROS promote IL-4 receptor activation by oxidatively 
inactivating PTP1B, which physically associates with and deactivates IL-4 
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receptor. However, ROS are not required for the initiation of IL-4 receptor 
activation. ROS generated by activated erythropoietin receptor also promote IL-4 
signaling. These data reveal that inactivation of receptor-associated PTP-activity 
by cytokine-generated ROS is a physiologic mechanism for the amplification of 
cytokine receptor activation in both cis and trans, unfolding a novel means of 
cytokine signaling cross-talk. 
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3.2. Introduction 
PTPs are a family consisting of a wide variety of receptor-like and non-
transmembrane enzymes. PTPs serve as important regulators for many different 
signaling pathways and are characterized by remarkably high in vivo substrate 
specificity. Much though remains to be elucidated about the regulatory 
mechanisms determining the activity of PTPs. Recent evidence suggests that at 
least some PTPs can be regulated by oxidative inactivation. 
Protein tyrosine phosphorylation is a reversible and tightly regulated 
biochemical event. The forward and reverse reactions are catalyzed by receptor-
associated Jaks and protein tyrosine phosphatases (PTPs) respectively (Haque 
and Sharma, 2006; Heldin, 1995). In the absence of cytokine engagement, 
receptor-associated PTP activity dominates over the Jak activity, thereby holding 
the receptor in an inactive state (Fischer et al., 1991; Haque and Sharma, 2006). 
Engagement of cytokine causes aggregation of receptor chains, bringing their 
associated Jak molecules into an appropriate proximity. This allows the trans-
phosphorylation of Jaks on signature tyrosine residues, which increases their 
catalytic activities, thereby promoting the forward reaction and stabilizing the 
receptor activation (Haque and Sharma, 2006; O'Shea et al., 2002).  
This mechanism of receptor activation is well established for the majority 
of cytokines including IL-4. However, in principle, inactivation of receptor-
associated PTPs could be an alternate means of receptor activation. The 
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catalytic cysteine residue of PTPs are susceptible to oxidative inactivation (Rhee 
et al., 2000; Tonks, 2005; Tonks, 2006).  
Our laboratory has previous reported that, vanadium peroxide (pervanadate) 
causes irreversible oxidation of catalytic Cys of PTPs, which in turn increases the 
tyrosine phosphorylation of many cytokine-signaling proteins in the absence of 
cytokine-stimulation of cells. In a subsequent study, we have demonstrated that 
pervanadate-mediated inactivation of IL-4 receptor-associated PTP activity, 
which controls the Jak1 function, leads to a ligand-independent activation of 
STAT6. These results strongly suggest that IL-4 receptor-associated PTP activity 
functions as a primary negative regulator of the signaling pathway, and the PTP 
activity is regulated by the redox status of the receptor microenvironment.  
All PTPs contain an eleven amino acid signature motif [(Ile/Val)-His-Cys-
X-Ala-Gly-X-X-Arg-(Ser/Thr)-Gly] (X is any amino acid), in which the Cys is 
essential for catalysis. It is shown that the Cys-thiolate anion (Cys-S-) is more 
susceptible to oxidation by H2O2 than Cys-SH ( Denu and Dixon, 1998; Denu and 
Tanner, 1998). The catalytic Cys of PTPs can be readily oxidized by H2O2 and 
other oxidants. Given that thiolate anion (PTP-Cys-S-) is the reactive form of the 
enzyme, peroxide-mediated oxidation of signature motif Cys can inactivate the 
catalytic function of the PTPs.  
To this end, our laboratory, and others, have previously identified SHP-1 
and CD45 as negative regulators of this pathways (Haque et al., 1998; Yamada 
et al., 2002). However the PTPs investigated are expressed exclusively in 
hematopoietic cells (Irie-Sasaki et al., 2001).  Since functional IL-4 receptor is 
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expressed in almost all cell types (Nelms et al., 1999), it is important to identify 
ubiquitously expressed PTPs that dephosphorylate and deactivate IL-4 receptor.   
In the previous chapter, we demonstrated that ROS are generated 
immediately after IL-4 stimulation of both hematopoietic and non-hematopoietic 
cells, which promote IL-4 receptor activation and subsequent signal transduction. 
Here, we show that this is mediated by ROS-dependent oxidative inactivation of 
PTP1B, a ubiquitously expressed PTP that physically associates with and 
deactivates IL-4 receptor. Further, we provide evidence that ROS generated by 
another cytokine, EPO, markedly amplify the activation of IL-4 receptor and 
consequent signal transduction in the same cells, suggesting that ROS can 
mediate cytokine signaling cross-talk.  
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3.3. Materials and Methods 
3.3.1. Cells and Reagents 
A549, 293T and NIH 3T3 cells were maintained in DMEM, supplemented 
with 10% fetal calf serum (FCS). Immortalized MEFs from Ptpn1+/+ and Ptpn1-/- 
mice were maintained in DMEM supplemented with 15% FCS (Buckley et al., 
2002). Single cell suspensions were prepared from mouse spleens, and cultured 
in IMDM supplemented with 10% FCS. Cells obtained by flushing the mouse 
femur bone marrow were cultured in complete DMEM supplemented with 10% 
FCS and 20% L929-conditioned medium (as a source of M-CSF) to differentiate 
them into macrophages (Haque et al., 1998). To develop mast cells, the bone 
marrow-derived cells were cultured for 3-4 weeks in RPMI supplemented with 
10% FCS, 10 mM HEPES, 1X MEM essential amino acids, 1 mM sodium 
pyruvate, 10 µM β-mercaptoethanol and 20% WEHI-3 conditioned medium (as a 
source of IL-3), and cells  were used when more than 95% of them stained 
positive with toluidine blue (Yuan et al., 1998).  
All recombinant cytokines and anti-oxy-PTP were purchased from R&D 
Systems. Apocynin, DPI, AG490, LY294002 and wortmannin were obtained from 
Calbiochem. Nifedipine, heparin and anti-FLAG conjugated agarose beads were 
purchased from Sigma. All antibodies used for T cell isolation, differentiation and 
analyses were from BD Pharmingen. Anti-phospho (Tyrosine641)-STAT6 and 
anti-phospho-tyrosine PY100 were purchased from Cell Signaling Technology, 
and anti-V5 was from Invitrogen. Anti-STAT6, anti-β-actin, anti-FLAG and anti-
goat HRP were obtained from Santa Cruz Biotechnology and anti-PTP1B was 
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from BD Transduction. Anti-mouse HRP and anti-rabbit HRP were purchased 
from Amersham Biosciences. All animal experiments were conducted according 
to the guidelines of our Institutional Animal Care and Use Committee.  
3.3.2. Intracellular ROS Assay 
ROS were measured fluorimetrically using CM-H2DCFDA probe (Choi et 
al., 2005; Myhre et al., 2003). Briefly, adherent cells were washed twice with 
Hank’s balanced salt solution (HBSS), incubated with 5 µM CM-H2DCFDA in 
HBSS for 10 min at 37°C in 5% CO2, washed and stimulated with indicated 
cytokine at 37°C under a Leica DMIRB inverted microscope (Leica Microsystems) 
equipped with a Retiga EXi Cooled CCD Camera (Q Imaging, Burnby), with a 
Ex490nm and standard fluorescein filter. Images were taken at every 10 sec, and 
fluorescence signals were quantified using Image Pro Plus Software (Media 
Cybernatics).  Each value in relative fluorescence units (RFU) represents mean ± 
SE of three independent measurements; each measurement represents the 
mean fluorescence signals of five equivalent fields (approximately same number 
of cells). To measure ROS for longer time periods (>5 min), cells were loaded 
with CM-H2DCFDA, trypsinized, resuspended in HBSS, and changes in 
fluorescence signals were measured using flow cytometry (FACScan, Beckton-
Dickinson).  ROS produced by non-adherent cells were measured using Victor2 
Wallace Mutichannel Reader (Perkin Elmer) using Ex495nm and Em535nm filters.  
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3.3.3. Electrophoretic Mobility Shift, Super-shift and Luciferase Assays 
EMSA was performed using 10 µg proteins of whole cell extracts and 0.2 
ng of 32P-labeled high-affinity STAT6-specific probe (Haque et al., 2000). Cell 
extracts were incubated with 2 µg of normal rabbit IgG or anti-STAT6 antibody 
prior to incubation with 0.2 ng of radiolabeled oligonucleotide duplex for 20 min 
for super-shift assay, or with 10 ng or 50 ng of unlabeled wild-type or mutant 
oligonucleotide duplex for competition assay. The sequences for the sense 
strand of the oligonucleotide are: 5’-GATCGCTCTTCTTCCCAGGAACTCA-ATG-
3’ (wild-type) and 5’-GATCG-CTCTTCTTCCCAGGGGCTCAATG-3’ (mutant) 
with the conserved N6-GAS sequence underlined (Haque et al., 2000), and the 
mutated nucleotides italicized. The DNA-protein complexes were resolved on 
native 6% polyacrylamide gels, dried and visualized after incubation at -80oC. 
Luciferase assay was performed using the Dual Luciferase Assay Kit (Promega) 
as per the manufacturer’s instructions. 
3.3.4. Cloning, Site-directed Mutagenesis and Plasmid Constructs 
Murine IL-4Rα cDNA was isolated from a NIH3T3 cell-derived cDNA 
library by PCR, and cloned in pcDNA3.1/V5-HisA (Invitrogen). For BRET assay, 
human IL-4Rα was cloned in pRLuc-N3, and STAT6 and PTP1B (D181A) in 
pGFP2-N2 (Perkin Elmer). All point mutants were generated using Quick Change 
XL Site-directed Mutagenesis Kit (Stratagene) following the manufacturer’s 
instructions.  
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DNA oligonucleotides encoding shRNA sequences with loop sequence 
(5’-TTC- AAGAGA-3’) were cloned into pSuper-Neo (OligoEngine) according to 
the manufacturer’s instructions. The specific target sense sequences were: 5’-
GAATTAGGCAAAGTGGGTT-3’ for NOX1, 5’-AAGAGCGATTCTTTGCCCTAT-3’ 
for NOX5L, 5’-CGGGAAGACAAGTTCA-TGTACTT-3’. The scramble versions of 
the target sequences were generated using siRNA Wizard (InVivogen), and 
cloned in pSuper-Neo vector (OligoEngine). All constructs were verified by 
nucleotide sequencing. 
3.3.5. Transfection and Generation of Stable Clones 
A549 and 293T cells were transfected using Lipofectamine 2000 
(Invitrogen) and calcium phosphate co-precipitation respectively (Haque et al., 
2000) with transfection efficiencies of 70-80% and ~90% respectively. Stable 
clones of immortalized PTP1B-deficient MEFs were generated by selection with 
150 µg/ml hygromycin B (Invitrogen) for 2 weeks.  
3.3.6. RT-PCR  
For determination of mRNA levels, 1.0 µg of total RNA was used for first-
strand cDNA synthesis according to the manufacturer’s protocol (Invitrogen). 
One-tenth of cDNA was used as a template for 35 cycles of PCR using specific 
primer sets listed in Table I.  
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3.3.7. In Vitro T Cell Differentiation  
Single-cell suspensions of mouse lymph node cells were incubated with 
FITC-conjugated anti-CD8, anti-B220, anti-MHC Class II (Fh2d) and anti-FcγR, 
followed by incubation with anti-FITC microbeads (Miltenyi Biotec). The negative 
fraction obtained after magnetic separation using an LS magnetic column 
(Miltenyi Biotec) contained >95% CD4+ T cells. These cells were stained with PE-
conjugated anti-CD44, and naïve CD4+ T cells were sorted using a 
FACSVantage SE cell sorter (Becton Dickinson). 1 x 106 purified naïve CD4+ T 
cells were cultured in 12-well plates in the presence of 3 µg/ml of anti-CD3 and 3 
µg/ml of anti-CD28, with 5 X 106 T-cell depleted splenocytes. For Th1 cell 
differentiation, murine IL-12 (10 ng/ml) and anti-IL-4 (10 µg/ml) were added to the 
culture media.  For Th2 cell differentiation, murine IL-4 (1000 U/ml) was added 
along with anti-IL-12 (10 µg/ml) and anti-IFN-γ (10 µg/ml). After 72 hr, the cells 
were harvested and restimulated with immobilized anti-CD3 (3 µg/ml) and anti-
CD28 (3 µg/ml) for 6 hr in the presence of 2 µM monensin (Calbiochem) for the 
last 2 hr. The cells were fixed with 4% paraformaldehyde, permeabilized in buffer 
(PBS containing 0.1% BSA, 0.5% Triton X-100), and stained with FITC-
conjugated anti-IFN-γ and PE-conjugated anti-IL-4. The expression of 
intracellular cytokines was determined using a FACSCalibur (Becton Dickinson), 
and analyzed using a FlowJo software (Treestar). 
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3.3.8. Chemical Cross-linking, Immunoprecipitation and Immunoblotting 
Chemical cross-linking, immunoprecipitation and immunoblotting of 
proteins were performed as described (Maiti et al, 2005). 
3.3.9. BRET Assay 
BRET assay was performed following the method of Pfleger and Eidne 
(Pfleger and Eidne, 2006). Briefly, 293T cells were transfected with 1.0  µg of the 
donor plasmid, pIL-4Rα-LUC-N3 and 3.0 µg of an acceptor plasmid pGFP2-N2 
(empty vector), STAT6-GFP2-N2 or PTP1B-D181A-GFP2-N2, using 
Lipofectamine 2000 (Invitrogen). After 48 hr, cells were washed with PBS and 
collected in BRET2 buffer (Dulbecco’s PBS supplemented with 0.05 g/l CaCl2, 
0.05 g/l MgCl2 and 0.1 g/l glucose), washed twice, and resuspended at 2.5 x 107 
cells/ml. Cell suspensions in 96-well plates (50 µl/well) were stimulated 20 ng/ml 
of IL-4 or left untreated, followed by addition of DeepBlueC (Perkin Elmer). 
Fluorescence signals were measured at every 30 sec using Victor3 Wallace 
Multichannel Reader (Perkin Elmer) with Ex395nm and Em510nm. For each time 
point, BRET ratio was calculated as: (Fluorescence510nm/luminescence) – 
(fluorescence510nm for donor only cells/Luminescence). Each point represents 
mean  ± SE (n=3). 
3.3.10. ROS-Induced Oxidation of PTP1B 
PTP1B oxidation was measured as described (Persson et al., 2004), with 
minor modifications. To eliminate spontaneous PTP1B oxidation during cell lysis, 
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buffers were extensively deoxygenated by bubbling nitrogen gas, and cell lysis 
was performed in an anaerobic chamber with a continuous flow of nitrogen gas. 
After indicated treatments, cells were washed with deoxygenated cold PBS, and 
lysed using deoxygenated lysis buffer (20 mM Tris, pH 7.5, 1% NP-40, 10% 
glycerol, 1 mM benzamidine and 1.4 µg/ml aprotenin) in the presence or absence 
of 100 mM iodoacetic acid (IAA). IAA alkylates all cysteines except the reversibly 
oxidized ones. Cell lysates were immunoprecipitated using anti-PTP1B, 
immobilized on protein G sepharose beads, and incubated with 10 mM DTT to 
reduce the reversibly oxidized cysteine of PTP1B which was subsequently 
oxidized irreversibly to cysteine-sulfonic acid by incubation with 100 µM PV for 1 
hr at 40C.  The samples were then used for immunoblotting with a monoclonal 
antibody raised against a peptide corresponding to the conserved PTP active site 
(‘Val-His-CysSO3H-Ser-Ala-Gly’) in which the catalytic cysteine (C215 in PTP1B) 
is irreversibly oxidized to cysteine-sulfonic acid.  
3.3.11. Statistical and Densitometric Analyses 
All experiments were performed at least three times. Statistical differences 
between different groups were determined using paired Student’s t-test. EMSA 
and immunoblot signals were quantified using ImageQuant (Molecular 
Dynamics).  
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3.4. Results 
3.4.1. PTP1B Downregulates IL-4 Receptor Activation 
Since ROS produced by IL-4 promote the activation of its receptor, we 
hypothesized that ROS generated by activated IL-4 receptor may oxidatively 
inactivate IL-4 receptor-associated PTP activity. Previously we and others have 
identified SHP-1 and CD45, which are exclusively expressed in hematopoietic 
cells, as negative regulators of IL-4 signaling (Haque et al., 1998; Yamada et al., 
2002). IL-4 induced ROS generation in all cell types examined. Therefore, it was 
important to identify a ubiquitously expressed PTP that deactivates IL-4 receptor. 
To this end, overexpression of a panel of ubiquitous PTPs in 293T cells identified 
PTP1B as a potential candidate which significantly inhibited IL-4-dependent 
STAT6 activation (Figure 3.1). Further, overexpression of wild-type but not 
catalytically inactive mutant PTP1B (C215S), markedly inhibited IL-4-dependent 
STAT6 activation (Figure 3.2) and subsequent gene expression in 293T cells 
(Figure 3.3). This was confirmed using immortalized embryonic fibroblasts 
derived from PTP1B-/- mice (Buckley et al., 2002; Elchebly et al., 1999) which 
exhibited significantly heightened STAT6 activation, in both magnitude and 
duration, in response to IL-4 stimulation (Figure 3.4). Moreover, IL-4-dependent 
STAT6 activation was inhibited when PTP1B was knocked-in in PTP1B-/- MEFs 
(Figure 3.5). IL-13 utilizes the type II IL-4 receptor for cell signaling (Nelms et al., 
1999). We found that IL-13-dependent STAT6 activation was significantly 
increased in PTP1B-/- MEFs (Figure 3.6).  
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PTPs may exhibit overlapping, redundant functions in cytokine-mediated 
cell signaling.  Since SHP-1 and CD45 inhibit IL-4 signaling in hematopoietic 
cells (Haque et al., 1998; Yamada et al., 2002), it was important to examine if 
PTP1B would also inhibit IL-4 signaling in hematopoietic cells.  Figure 3.7 shows 
that IL-4-dependent STAT6 activation was markedly increased in primary 
splenocytes derived from PTP1B-/- mice. Consistent with the results, PTP1B-
deficiency also increased IL-4-induced ROS generation in both MEFs (Figure 
3.8) and splenocytes (Figure 3.9). Further, when PTP1B was knocked-in to 
PTP1B-/- MEFs, IL-4-induced ROS production was significantly reduced (Figure 
3.8). PTP1B-deficiency also increased ROS production by IL-4 in mouse primary 
macrophages, mast cells and T cells, and by IL-13 in MEFs, splenocytes and 
macrophages (Figure 3.10). Taken together, these data demonstrate that PTP1B 
plays a non-redundant role in the negative regulation of IL-4 and IL-13 signaling 
in hematopoeitic and non-hematopoeitic cells.  
Next, we asked whether PTP1B-deficiency would favor the differentiation 
of naïve T helper cells to a Th2 lineage. We observed that CD4+CD44low (naïve) 
T cells isolated from lymph nodes of PTP1B-/- mice produced 2.3- and 1.4-fold 
enhancement in the levels of IL-4 under neutral and Th2-skewed conditions, 
respectively, compared with wild-type cells (Figure 3.11). These data suggest 
that PTP1B negatively controls Th2 differentiation of naive T helper cells in vitro. 
However, we also noted that under Th1-skewed condition, PTP1B-/- 
CD4+CD44low T cells increased the level of IFN-γ production by 1.4-fold, (Figure 
3.11).  Th1 differentiation is governed by IL-12- and IFN-γ signaling (Nelms et al., 
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1999). PTP1B binds to, and dephosphorylates Jak2, thereby attenuating IFN-γ 
signaling (Myers et al., 2001). Although PTP1B-mediated downregulation of IL-12 
signaling has not been demonstrated directly, Jak2 and TYK2, that are required 
for IL-12-mediated cell signaling (Haque and Sharma, 2006), are shown to be 
potential substrates for PTP1B. Therefore, it was not unexpected that PTP1B-
deficiency increased the number of IFN-γ producing cells under Th1-skewed 
condition (Figure 3.11).  
Next, to determine if PTP1B dephosphorylates IL-4 receptor, we used a 
chimeric receptor, EPOR-IL-4Rα, composed of the extracellular and 
transmembrane domains of the murine EPOR and the cytoplasmic domain of the 
human IL-4Rα  (Figure 3.12A). This receptor, when co-expressed with STAT6 in 
293T cells (which do not express endogenous, functional STAT6), forms 
homodimer upon EPO-binding, and induces STAT6 activation (Haque et al., 
2000). PTP1B significantly inhibited EPO-dependent tyrosine phosphorylation of 
EPOR-IL-4Rα, and subsequent activation of STAT6 in 293T cells (Figure 3.13), 
suggesting that PTP1B might interact with IL-4Rα, Jak1 or STAT6. However, a 
previous study has shown that Jak1 does not bind to PTP1B (Myers et al., 2001). 
To determine if PTP1B binds to IL-4Rα and/or STAT6, either wild-type PTP1B or 
substrate-trapping mutant PTP1B (D181A) (Flint et al., 1997), was co-expressed 
with EPOR-IL-4Rα and/or STAT6, in 293T cells. Subsequent co-
immunoprecipitation and Western analyses, however, failed to detect any 
association of PTP1B with either EPOR-IL-4Rα  or STAT6 (data not shown). To 
address the possibility of a weak and dynamic interaction occurring between 
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these proteins, cell lysates were prepared in the presence of the cross-linking 
agent, dithio[succimidyl propionate] (DSP), prior to immunoprecipitation (Maiti et 
al., 2005). We found that PTP1B formed a complex with the cytoplasmic domain 
of IL-4Rα, but not STAT6 (Figure 3.14). Further, using deletion mutants of 
EPOR-IL-4Rα  (Figure 3.12B), we demonstrated that PTP1B interacted with a 
region of IL-4Rα  harboring the STAT6-docking tyrosine residues (Nelms et al., 
1999) (Figure 3.12C).  
Bioluminescence resonance energy transfer (BRET) assay is a powerful 
tool for the detection of weak and dynamic protein-protein interactions in live cells 
(Pfleger and Eidne, 2006). Using this assay, an interaction between PTP1B 
(D181A) and IL-4Rα was detected even in the absence of IL-4 stimulation, which 
was increased in the presence of IL-4 (Figure 3.15). These results confirmed the 
in vitro cross-linking data indicating PTP1B physically associates with IL-4Rα. 
3.4.2. ROS Inactivate PTP1B by Oxidation of Its Catalytic Cysteine, and 
Serve as a Mediator of Cytokine Cross-Talk 
ROS-mediated oxidative inactivation of PTP1B has been demonstrated 
both in vitro (Salmeen et al., 2003; van Montfort et al., 2003), and in vivo by 
insulin and EGF (Lee et al., 1998; Mahadev et al., 2001; Meng et al., 2002). 
Since we found that IL-4 induced ROS production (Figure 2.1), and that PTP1B 
deactivated IL-4 receptor, it was important to examine if IL-4-generated ROS 
could cause oxidative inactivation of PTP1B. Using a monoclonal antibody raised 
against oxidized PTP-active site (Persson et al., 2004), we observed a time-
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dependent oxidation of the catalytic cys215 of PTP1B in A549 cells after 
stimulation with IL-4 (Figure 3.16) or IL-13 (Figure 3.17). Further, pretreatment of 
these cells with apocynin or LY294002 that completely inhibited IL-4-mediated 
ROS production significantly reduced the oxidation of PTP1B (Figure 3.18). 
Moreover, shRNA-mediated reduction of NOX1 or NOX5 expression, which 
significantly decreased IL-4-induced ROS generation, inhibited IL-4-dependent 
oxidation of PTP1B (Figure 3.19). IL-4 also induced a time-dependent oxidation 
of PTP1B in primary mouse splenocytes (Figure 3.20A), and primary bone 
marrow-derived macrophages (Figure 3.20B). These results clearly demonstrate 
that ROS-mediated amplification of IL-4 (or IL-13) signaling is, in part, due to 
oxidative inactivation of PTP1B, in both primary and immortalized cells. 
Under physiologic settings, multiple cytokines may act on a single cell that 
expresses its cognate receptor(s). Since ROS are small, diffusible radicals or 
molecules, it is possible that oxidative inactivation of PTP1B by other cytokine-
generated ROS may amplify the activation of IL-4 receptor in the same cell. To 
examine this possibility, the mutant murine IL-4Rα (Tyr500Phe) that did not 
generate ROS but supported STAT6 activation, in response to murine IL-4 
stimulation, was expressed in A549 cells. Upon simultaneous treatment of these 
cells with EPO and murine IL-4, a significant increase (1.2-fold) in STAT6 
activation was observed (Figure 3.21). EPO did not activate STAT6 (Figure 3.21) 
but induced ROS production in these cells (Figure 3.22). These results suggest 
that EPO-generated ROS can act in trans to promote IL-4 signaling in the same 
cell. Further, to examine if EPO or other cytokines can promote IL-4 signaling 
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through its endogenous receptor, A549 cells were pretreated with EPO or TNF-α 
followed by treatment with IL-4, in the presence or absence of PI3K inhibitor, 
LY294002. Both EPO and TNF-α markedly promoted the activation of 
endogenous IL-4 receptors in A549 cells (Figure 3.23). Similar observations were 
made in mouse primary splenocytes where ROS generated by IL-3 and TNF-α 
(Figures 3.24A & B) significantly increased IL-4-dependent STAT6 activation 
(Figures 3.25A & B). Of note, LY294002 completely blocked EPO- and TNF-α-
induced ROS generation in A549 cells, but failed to completely compromise IL-3- 
and TNF-α-induced ROS production in primary splenocytes (Figures 3.25), 
suggesting that IL-3 and TNF-α may also induce ROS production by PI3K-
independent mechanism(s). Importantly, these were consistent with trans-
activation levels of IL-4 signaling in the respective cells.  
Collectively, these results demonstrate, for the first time, that ROS 
produced by activation of other cytokine receptors were able to enhance the 
activation of IL-4 receptor in the same cells, suggesting that ROS can serve as a 
physiologic mediator of cross-talk between different cytokine receptors. 
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Figure 3.1: PTP1B Negatively Controls IL-4 Signaling 
Overexpression of PTP1B inhibits IL-4-dependent STAT6 activation. 293T cells 
were transfected with 0.1 µg of STAT6 expression construct along with 4.0 µg of 
PTP1B, TC-PTP, SHP-1 (as a positive control), SHP-2 construct or respective 
empty vector. After 48 hr, cells were treated with IL-4 (20 ng/ml) for 30 min, and 
cell extracts were subjected to EMSA and Western analyses.  
 
 
 
 
 
Figure 3.2: Phosphatase Activity of PTP1B is required for Inhibition of IL-4 
dependent STAT6 Activation. 
293T cells were transfected with 0.1 µg of STAT6 expression construct along 
with 4.0 µg of wild-PTP1B, phosphatase-dead mutant PTP1B (C215S) or vector. 
After 48 hr, cells were treated with IL-4 (20ng/ml) for 30 min, and cell extracts 
were subjected to EMSA. 
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Figure 3.3: PTP1B Inhibits IL-4- and IL-13-dependent Gene Expression.  
293T cells were transfected with 0.1 µg of STAT6 expression plasmid and 4.0 µg 
of STAT6-responsive luciferase construct, along with indicated amounts of wild-
type or phosphatase-dead mutant PTP1B (C251S), or with 5.0 µg of vector. After 
24 hr, transfected cells were split in 1:3; and treated for 18 hr with IL-4 (10 
ng/ml), IL-13 (10 ng/ml), or left untreated. Normalized luciferase activities in 
arbitrary units (AU) are plotted as mean ± SE, (n=3) (** = P < 0.01).  
 
 
 
 
94 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: PTP1B Deficiency Increases IL-4-dependent STAT6 Activation in 
MEFs.  
Immortalized MEFs derived from PTP1B+/+ and PTP1B-/- mice were treated with 
IL-4 (20 ng/ml) for the indicated periods, and cell extracts were subjected to 
EMSA or Western analyses, and RSI quantified.  
 
 
 
 
 
 
 
 
Figure 3.5: Knocking-in of PTP1B in PTP1B-/- MEFs Reduces IL-4-dependent 
STAT6 Activation. 
Immortalized PTP1B-/- MEFs were stably transfected with either vector or PTP1B, 
and clones were selected in the presence of hygromycin B. Selected pools were 
treated with IL-4 (20 ng/ml) for 30 min, and cell extracts were subjected to 
Western analyses and EMSA. 
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Figure 3.6: PTP1B-deficiency Increases IL-13-dependent STAT6 Activation in 
MEFs. 
Immortalized MEFs derived from PTP1B+/+ and PTP1B-/- mice were treated with IL-
13 (10 ng/ml) for the indicated periods. Cell extracts were subjected to EMSA and 
RSI quantified. 
 
 
 
 
 
 
 
 
 
Figure 3.7: PTP1B-deficiency Increases IL-4-dependent STAT6 Activation in 
Mouse Primary Splenocytes.  
Splenocytes from PTP1B+/+ and PTP1B-/- mice were treated with IL-4 (20 ng/ml) for 
the indicated periods, cell extracts were subjected to EMSA and RSI quantified. 
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Figure 3.8: PTP1B-deficiency Increases IL-4-dependent ROS Generation in 
MEFs.  
Immortalized MEFs derived from PTP1B+/+ and PTP1B-/- mice, and representative 
clones of PTP-/- MEFs stably transfected with PTP1B (or vector) were examined for 
IL-4-induced ROS production. RFU are plotted as mean ± SE, (n=3) (* = P < 0.05; ** 
= P < 0.01).  
 
 
 
 
 
 
 
 
Figure 3.9: PTP1B-deficiency Increases IL-4-dependent ROS Generation in 
Mouse Primary Splenocytes.  
Splenocytes isolated from PTP1B+/+ and PTP1B-/- mice were examined for IL-4-
induced ROS production in RFU plotted as mean ± SE, (n=3) (** = P < 0.01). 
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Figure 3.10: PTP1B-deficiency Results in Increased ROS Production by IL-4 or 
IL-13.  
(A) Immortalized MEFs derived from PTP1B+/+ and PTP1B-/- mice were examined for 
IL-13-induced ROS production, and RFU plotted as mean ± SE, (n=3) (** = P < 
0.01).  
(B) Primary splenocytes derived from PTP1B+/+ and PTP1B-/- mice were examined 
for IL-13-induced ROS production, and RFU plotted as mean ± SE, (n=3) (** = P < 
0.01). 
(C & D) Primary macrophages derived from bone marrows of PTP1B+/+ and PTP1B-/- 
mice were examined for IL-4- (C) and IL-13- (D)-induced ROS production, and RFU 
plotted as mean ± SE, (n=3) (** = P < 0.01).  
(E) Primary mast cells derived from bone marrows of PTP1B+/+ and PTP1B-/- mice 
were examined for IL-4-induced ROS production, and RFU plotted as mean ± SE, 
(n=3) (** = P < 0.01). 
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(F) Naïve CD4+ T cells derived from lymph nodes of PTP1B+/+ and PTP1B-/- mice 
were examined for IL-4-induced ROS production, and RFU plotted as mean ± SE, 
(n=3) (** = P < 0.01). 
 
 
 
 
 
 
 
 
Figure 3.11: PTP1B-deficiency Increases Number of IL-4-producing CD4+ T 
cells.  
Naïve CD4+ T cells were purified from lymph nodes of PTP1B+/+ and PTP1B-/- mice, 
and cultured with T-cell depleted syngenic irradiated spleen cells as a source of 
antigen-presenting cells, at a ratio of 1:5, for 72 hr under conditions to induce Th0, 
Th1 or Th2 differentiation. Intracellular IL-4 and IFN-γ levels were determined 
following re-stimulation with anti-CD3 and anti-CD28 antibodies.  
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Figure 3.12: PTP1B Associates with the Cytoplasmic Domain of IL-4Rα. 
(A) Schematic representation of the EPOR-IL-4Rα chimeric receptor. The 
numbers in parentheses indicate the corresponding amino acids of human IL-
4Rα. 
(B) Schematic representation of the EPOR-IL-4Rα deletion mutants.  
(C) PTP1B interacts with a specific region of IL-4Rα. 293T cells (1.2 x 106 cells 
per 10-cm plate) were transfected with 4.0 µg of PTP1B (D181A) (tagged with 
FLAG) along with 2.0 µg of empty vector, wild-type or individual deletion mutant 
of EPOR-IL-4Rα (tagged with V5). After 48 hr, cell lysates were prepared in the 
presence of DSP, and proteins cross-linked to PTP1B were immunoprecipitated 
using anti-FLAG antibody. The immunoprecipitated complexes (and cell lysates) 
were decross-linked by boiling in the presence of 2-mercaptoethanol, and 
subjected to Western analyses. 
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Figure 3.13: PTP1B Deactivates IL-4Rα.  
293T cells were transfected with 50 ng of STAT6 and 5.0 µg of chimeric EPOR-
IL-4Rα−V5, along with 5.0 µg of PTP1B or vector. After 48 hr, cells were treated 
with EPO (5 U/ml) for 5 min, and cell extracts were subjected to EMSA.  
Immunoprecipitate derived from 1.0 mg protein or 50 µg of cell lysate proteins 
were analyzed by Western blotting. The experiment was repeated twice and 
similar results were obtained. 
 
 
 
Figure 3.14: PTP1B Physically Associates with the Cytoplasmic Domain of 
IL-4Rα.  
In lanes 1 to 6, 293T cells were transfected with EPO-IL-4Rα-V5 (2 µg), 
untagged STAT6 (2 µg) and 4 µg of wild-type PTP1B, mutant PTP1B (D181A) or 
empty vector. In lanes 7 to 12, cells were transfected with 2 µg of STAT6-V5 and 
4 µg wild-type PTP1B, mutant PTP1B (D181A) or empty vector. After 48 hr, cells 
were treated with EPO (5 U/ml) or IL-4 (20 ng/ml) for 5 min. Cell lysates were 
prepared in the presence of DSP and immunoprecipitated (IP) with anti-FLAG 
antibody, decross-linked and subjected to Western analyses along with decross-
linked total lysates. 
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Figure 3.15: PTP1B Interacts with IL-4Rα in Live Cells.  
For BRET assay, 293T cells were transfected with 1.0 µg of the donor plasmid, pIL-
4Rα-Luc-N3 and 3.0 µg of an acceptor plasmid pGFP2-N2 (empty vector), STAT6-
GFP2-N2 or PTP1B-D181A-GFP2-N2 using Lipofectamine 2000 (Invitrogen). After 
48 hr, cells were used for BRET assay, and the calculated BRET ratios plotted as 
mean ± SE, (n=3).  
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Figure 3.16: Oxidation of PTP1B in IL-4-stimulated A549 Cells. 
Cells were treated with 20 ng/ml of IL-4 for indicated lengths of time, with 3 mM H2O2 (positive control) for 5 min, or left untreated. Cell lysates were prepared in the 
presence (upper panel) or absence (lower panel) of iodoacetic acid (IAA), 
immunoprecipitated using anti-PTP1B antibody, and the immune complexes were 
subjected to Western analysis using a monoclonal antibody that recognizes the 
oxidized form of PTP1B.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17: Oxidation of PTP1B in IL-13-stimulated A549 Cells.  
Cells were treated with 10 ng/ml of IL-13 for indicated lengths of time, with 3 mM 
H2O2 (positive control) for 5 min, or left untreated. Cell lysates were prepared in the 
presence (upper panel) or absence (lower panel) of iodoacetic acid (IAA), 
immunoprecipitated using anti-PTP1B antibody, and the immune complexes were 
subjected to Western analysis using a monoclonal antibody that recognizes the 
oxidized form of PTP1B.  
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Figure 3.18: Blockade of ROS Production Inhibits PTP1B Oxidation in IL-4-
stimulated Cells.  
A549 cells were treated with 500 µM apocyanin, 20 µM LY294002 or DMSO for 2 hr 
prior to measuring IL-4-mediated oxidation of PTP1B. The upper and lower panels 
represent results derived from cell lysates prepared in the presence and absence of 
IAA respectively. The experiment was repeated two times and similar results were 
obtained. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.19: Blockade of ROS Production Inhibits PTP1B Oxidation in IL-4-
stimulated Cells.  
A549 cells were transfected with 4.0 µg of shRNA or scrambled constructs for NOX1 
or NOX5. After 48 hr, cells were treated for 5 min with IL-4 (20 ng/ml), left untreated 
(negative control) or treated with 3 mM H2O2 (positive control) for 5 min. Cell lysates 
were prepared in the presence (upper panel) or absence (lower panel) of IAA, and 
PTP1B oxidation measured.  
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Figure 3.20: IL-4-generated ROS Induce PTP1B Oxidation in Mouse Primary 
Hematopoeitic Cells.  
(A) Splenocytes were stimulated with IL-4 for indicated lengths of time or with 3 mM 
H2O2 (positive control) for 5 min. Cell lysates were prepared in the presence (upper 
panel) or absence (lower panel) of IAA, and PTP1B oxidation measured. 
(B) Bone marrow-derived macrophages were stimulated with IL-4 for indicated 
lengths of time or with 3 mM H2O2 (positive control) for 5 min. Cell lysates were 
prepared in the presence (upper panel) or absence (lower panel) of IAA, and PTP1B 
oxidation measured. 
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Figure 3.21: EPO-generated ROS Promote IL-4-dependent STAT6 Activation.  
A549 cells were transfected with 1.0 µg of murine IL-4Rα  (Y500F), along with 3.0 µg 
of murine STAT6 plasmid. After 48 hr, cells were treated for 5 min with EPO (5U/ml) 
and murine IL-4 (20 ng/ml), either singly or in combination. Cell extracts were 
subjected to EMSA and RSI quantified.  
 
 
 
Figure 3.22: Cytokine-induced ROS Generation in A549 Cells. 
A549 cells were pretreated for 2 hr with LY294002 (20 µM) or DMSO, and ROS 
production measured after stimulation with IL-4 (20 ng/ml), EPO (5U/ml) or TNF-α 
(10 ng/ml). RFU plotted as mean ± SE, (n=3). 
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Figure 3.23: TNF-α and EPO-generated ROS Promote Endogenous IL-4 
Receptor Activation in A549 cells.  
Cells pretreated with LY294002 (20 µM) or DMSO for 2 hr, were stimulated for 3 min 
with EPO (5U/ml) or TNF-α (10 ng/ml) followed by treatment with human IL-4 (20 
ng/ml) for 2 min. Cell extracts were subjected to EMSA, and RSI quantified.  
 
 
 
Figure 3.24: Cytokine-induced ROS Generation in Mouse Primary Splenocytes.  
(A) Mouse primary splenocytes were pretreated for 2 hr with LY294002 (20 µM), 
apocynin (500 µM) or DMSO, and ROS were measured after 1 min stimulation with 
IL-4 (20 ng/ml) and TNF-α (10 ng/ml). RFU plotted as mean ± SE, (n=3). 
(B) Mouse primary splenocytes were pretreated for 2 hr with LY294002 (20 µM), 
apocynin (500 µM) or DMSO, and ROS were measured after 1 min stimulation with 
IL-4 (20 ng/ml) and IL-3 (10 ng/ml) . RFU plotted as mean ± SE, (n=3). 
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Figure 3.25: TNF-α- and IL-3-generated ROS Promote Endogenous IL-4 
receptor Activation in Mouse Primary Splenocytes.   
(A) After pretreatment for 2 hr with LY294002 (20 µM) cells were treated for 3 min 
with TNF-α (10 ng/ml) or IL-3 (10 ng/ml) followed by treatment with mouse IL-4 (20 
ng/ml) for 2 min. Cell extracts were subjected to EMSA and RSI quantified.  
(B) After pretreatment for 2 hr with apocynin (500 µM), cells were treated for 3 min 
with TNF-α (10 ng/ml) or IL-3 (10 ng/ml) followed by treatment with mouse IL-4 (20 
ng/ml) for 2 min. Cell extracts were subjected to EMSA and RSI quantified.  
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3.5. Discussion 
In the previous chapter, we have demonstrated, for the first time that 
immediately following IL-4 engagement, activated IL-4 receptor produced ROS that, 
in turn, increased the magnitude of receptor activation and consequent signal 
transduction, in the absence of de novo protein synthesis. Subsequently, we have 
defined the biochemical mechanisms by which IL-4 generated ROS. Here, we have 
identified PTP1B, as a ubiquitously expressed PTP, that associated with IL-4 
receptor and that was oxidatively inactivated by IL-4-generated ROS. Finally, we 
have uncovered a novel mechanism of ROS-mediated cytokine signaling cross-talk, 
which may provide a basis for side effects associated with cytokine therapies. 
Although IL-4-generated ROS oxidized PTP1B, which deactivated IL-4 receptor, 
ROS did not initiate receptor activation, but significantly enhanced IL-4-dependent 
receptor activation.  
Here, we demonstrate, for the first time, that PTP1B is a physiological target 
of IL-4-generated ROS in both hematopoietic and non-hematopoietic cells. Using 
PTP1B-deficient fibroblasts and splenocytes, we clearly demonstrate that PTP1B 
functions as a negative regulator of IL-4 receptor activation and subsequent signal 
transduction.  However, SHP-1 and CD45, which negatively regulate IL-4 signaling 
in hematopoietic cells  (Haque et al., 1998; Yamada et al., 2002), could also be 
potential targets of IL-4-generated ROS.  
PTP1B inactivates Jak2 and TYK2 and TC-PTP inactivates Jak1 and Jak3 
(Myers et al., 2001). We found that overexpression of PTP1B, but not TC-PTP 
inhibited IL-4-mediated STAT6 activation. Further, PTP1B inhibited IL-4 signaling in 
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hematopoeitic cells (splenocytes) that primarily signal through the type I IL-4 
receptor composed of Jak1-associated IL-4Rα and Jak3-associated γc (Nelms et al., 
1999). Also, PTP1B inhibited the activation of the chimeric EPO-IL-4Rα receptor 
that, associates only with Jak1. The protein-protein interaction studies using 
chemical cross-linking agent and BRET assay revealed that PTP1B interacted with 
Jak1-associated IL-4Rα even in the absence of IL-4 stimulation where IL-4Rα did 
not form complex with IL-13Rα1-asscociated Jak2/TYK2.  While, it is possible that 
PTP1B may target Jak2/TYK2 in type II receptor complex, our results clearly 
demonstrated that IL-4Rα was a primary target of PTP1B. This was further 
supported by our results that PTP1B did not interact with STAT6, and that STAT6 
activation was not required for IL-4-dependent ROS generation, which is regulated 
by PTP1B. 
ROS are diffusible molecules that inactivate PTPs including PTP1B (Rhee et 
al., 2000). Using IL-4 as a model cytokine, here we uncover a novel cellular 
mechanism underlying the amplification of cytokine receptor activation and signal 
transduction, by addressing how ROS generated by IL-4 receptor to promote its own 
activation as well as the activation of other cytokine receptors in the same cells. 
ROS-mediated cytokine signaling cross-talk may be dependent on the proximity of 
the different cytokine (or growth factor) receptors, and their susceptibility to 
regulation by oxidative inactivation of common PTPs. Another level of regulation 
may be provided by the specificity of the antioxidant proteins utilized by different 
receptors for elimination of cytokine-mediated ROS, allowing the regeneration of 
reversibly inactivated PTPs and restoration of normal homeostasis of cellular 
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cytokine signaling. Unfolding of the ROS-mediated cytokine signaling cross-talk may 
explain the causes of side effects of cytokine therapies in a variety of human 
diseases.  
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CHAPTER IV 
HOMEOSTATIC REGULATION OF IL-4 SIGNALING BY ANTIOXIDANTS 
 
 
 
4.1. Abstract 
We have previously shown that interleukin (IL)-4 induces the production of ROS, 
which, in turn, promote receptor activation by oxidatively inactivating PTP1B that 
deactivates the receptor. Here, we show that the redox state of cells regulated the 
magnitude of IL-4 receptor activation and signal transduction. Specifically, 
antioxidant enzymes superoxide dismutase (SOD)2, catalase and glutathione 
peroxidase (GPx)1, peroxiredoxin (Prx) II, Prx IV and Prx VI served as negative 
regulators of IL-4 signaling.  Moreover, Prx II, Prx IV and Prx VI but not SOD2, 
catalase or GPx1, formed complexes with IL-4 receptor. We also demonstrate that 
Prx II was oxidatively inactivated by IL-4-generated ROS. Furthermore, Prx II-
deficiency upregulates the oxidative inactivation of PTP1B in IL-4 stimulated cells. 
Collectively, these data suggest that antioxidant enzymes restore the homeostatic 
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control of IL-4 signaling by scavenging ROS, thereby acting as physiological 
negative regulators of IL-4 signaling pathways. 
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4.2. Introduction 
IL-4, an immunomodulatory cytokine, produced by activated Th2 
lymphocytes, basophils and mast cells, regulates a variety of immune responses 
including induction of Th2-differentiation, immunoglobulin class-switching, B cell 
proliferation, suppression of Th1-differentiation and macrophage activation among 
others (Nelms et al., 1999; Haque and Sharma, 2006).  IL-4 executes these 
pleiotropic functions by engaging its transmembrane receptor which activates two 
major intracellular signaling pathways, IRS-PI3K and STAT6. Protein tyrosine 
phosphorylation, a reversible reaction that is tightly regulated in mammalian cells, 
functions as a ‘signaling switch’ in cytokine-dependent signal transduction (Nelms et 
al., 1999). In a resting cell, the ‘signaling switch’ remains off due to receptor-
associated PTP activity which dominates over the PTK-catalyzed forward reaction 
(Tonks, 2006). Upon IL-4 engagement, IL-4Rα which remains constitutively 
associated with Jak1, recruits γc a secondary receptor to the complex, to form the 
type I receptor complex. IL-13Rα1 recruitment forms the type II receptor complex. 
The γc and IL-13Rα1 remain constitutively bound to Jak3 and Jak2 (or Tyk2) 
respectively. The formation of IL-4 receptor complex brings two Jak molecules to an 
appropriate proximity allowing them to trans-phosphorylate each other at the 
invariant tyrosine residues located in their activation loops (Nelms et al., 1999). This 
increases the catalytic activities of the Jaks, which then override the receptor-
associated PTP activity and initiate tyrosine phosphorylation in IL-4Rα (Nelms et al., 
1999). We have shown in Chapter II that immediately following its activation, IL-4 
receptor activates the IRS-PI3K-NOX pathway to generate ROS including O2– and 
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H2O2. In Chapter III, we have shown that ROS, in turn, promote IL-4 receptor 
activation and signal transduction, by oxidatively inactivating PTP1B that physically 
associates with and deactivates the receptor. We have also demonstrated in 
Chapter III that ROS generated by other cytokine receptors, including those for EPO, 
TNF-α or IL-3, also promote IL-4 receptor activation in the same cell. 
The magnitude and duration of a given cytokine action are tightly regulated by 
physiologic requirements. This relies on a delicate balance between 
physicochemical events that initiate and amplify the activation of cytokine receptor 
and subsequent signal transduction and those which attenuate and inactive the 
processes.  Because, ROS are found to amplify the IL-4 signaling, we have asked 
whether cellular antioxidants can dampen the IL-4 signals, and how an IL-4 
stimulated cell eliminates ROS, which would otherwise produce oxidative damage to 
the cell.   
Mammalian cells are well equipped with antioxidant enzymes that eliminate 
ROS and prevent oxidative damages. For example, superoxide dismutase (SOD) 
converts O2- to H2O2, which is further converted to H2O and O2 by catalase. The 
glutathione system complements the catalase by providing the reducing equivalents 
(Cantin et al., 1991). GPx uses reduced GSH that serves as the electron donor and 
is converted to glutathione disulphide (GSSG), which is subsequently converted to 
reduced GSH by glutathione reductase (GR) (Meister, 1983; Deneke, 1989). GR 
obtains electrons from NADPH that is produced by the hexose monophosphate 
shunt system (Meister, 1983; Deneke, 1989). 
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Another family of proteins called peroxiredoxins (Prx’s) eliminates low levels 
of H2O2 produced by mammalian cells in response to growth factors and cytokine 
stimulation of cells (Wood et al., 2003; Rhee et al., 2005). Prxs are thiol-containing 
peroxidases which are conserved from bacteria to mammals (Wood et al., 2003; 
Rhee et al., 2005). Prxs reduce hydroperoxides and peroxynitrite (produced by the 
reaction of NO [nitric oxide] and O2-) with electrons donated by physiologic thiols 
like thioredoxin (Rhee et al., 2005). Mammals express six Prx proteins, Prx I-VI. 
Based on the number and location of Cys residues that participate in the catalysis, 
Prxs are classified in three subgroups: typical 2-Cys, atypical 2-Cys and 1-Cys 
(Wood et al., 2003; Rhee et al., 2005). The typical 2-Cys subgroup is comprised of 
four family members, Prx I-IV, which are differentially distributed in subcellular 
compartments (Wood et al., 2003; Rhee et al., 2005). Prx I and Prx II are located in 
the cytosol, Prx III in mitochondria and Prx IV in the extracellular space as well as 
cytosol (Wood et al., 2003; Rhee et al., 2005). The atypical 2-Cys subgroup is 
comprised of Prx V, which is located in mitochondria and peroxisomes and Prx VI, 
which is abundant in the cytosol (Rhee et al., 2005). The catalytic Cys may be 
hyper-oxidized to Cys-sulfenic acid, which in the case of 2-Cys Prxs is slowly 
reduced to the active thiol form in an ATP-dependent process (Rhee et al., 2005).  
Here we show that antioxidant enzymes including SOD2, catalase, GPx1 and 
Prx’s (II, IV and VI) suppress IL-4 receptor activation and subsequent signal 
transduction, thereby restoring the homeostatic control of IL-4 receptor activation, 
signal transduction and subsequent gene expression by eliminating ROS produced 
by IL-4 stimulation of cells. 
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4.3. Materials and Methods 
4.3.1. Cells and Reagents 
Human embryonic kidney cell line 293T was cultured in DMEM supplemented 
with 10% heat-inactivated fetal bovine serum (Cellgro, Herndon, VA, USA), 2 mM L-
glutamine and 50 mg/liter of penicillin and streptomycin. The immortalized PrxII-/- and 
PrxII+/+ mouse embryonic fibroblasts were cultured in DMEM supplemented with 
15% heat-inactivated fetal bovine serum (FBS) (Hyclone, USA), 2 mM L-glutamine 
and 50 mg/liter of penicillin and streptomycin, as described (Kang et al., 1998; Kang 
et al., 2004). The primary splenocytes derived from PrxII-/- and PrxII+/+ mice were 
cultured in DMEM supplemented with 10% FBS (Hyclone, USA), 2 mM L-glutamine 
and 50 mg/liter of penicillin and streptomycin. Recombinant human and murine IL-4 
were purchased from R&D Systems. 
For the isolation of primary splenocytes, 5 female mice of each genotype, 6-
12 weeks of age, were sacrificed and whole spleen was transferred to a 6-cm petri 
dish containing 3 ml of culture medium.  The spleen was cleaned and teased into 
approximately 1 mm pieces. The cell clumps were transferred to a sterile 15 ml 
centrifuge tube, and the large tissue clumps were allowed to settle and the 
supernatant was transferred to a fresh 15 ml tube containing 10 ml of culture 
medium, and centrifuged at 750 g for 5 minutes at 25 oC to pellet the splenocytes. 
The pelleted splenocytes were washed twice with fresh culture medium by 
centrifugation, and resuspended (107 cells/ml) in culture medium (RPMI-1640 + 10% 
FBS + 50 U/ml penicillin + 50 µg/ml streptomycin + 2mM glutamine + 1mM sodium 
pyruvate + 2.5 µM β-mercaptoethanol). 
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4.3.2. Cloning, Site-Directed Mutagenesis and Plasmid Constructs 
Human Prx 1 and Prx II cDNA constructs were obtained as kind gifts from Dr. 
Sue Goo Rhee (Kang et al., 1998). The human Prx IV and Prx VI cDNA constructs 
were purchased from Origene Technologies (Rockville, MD). They were used as a 
template for PCR amplification and cloning in pcDNA3-HA in the BamHI-EcoRI sites. 
All point mutants were generated using Quick Change XL Site-directed Mutagenesis 
Kit (Stratagene) following the manufacturer’s instructions. For generation of stable 
clones in MEFs, wild-type and mutant Prx I and Prx II constructs were excised from 
pcDNA3-HA and cloned in HindIII-XhoI sites of pcDNA3.1/Hygro+ (Invitrogen). The 
FLAG-tagged mouse Gpx1 construct was a kind gift from Dr. Roger A Sunde (Weiss 
and Sunde, 1998). The human catalase, SOD1 and SOD2 cDNA constructs were 
purchased from Open Biosystems (Huntsville, AL) and used as template for PCR 
amplification and cloning in pcDNA3.1/V5-HisA (HindIII-Xba1 sites for catalase, and 
HindIII-XhoI sites for SOD1 and SOD2). All constructs were verified by nucleotide 
sequencing. Please refer to Table II for a complete list of primers that were used to 
clone the various antioxidant enzymes. 
4.3.3. Transient Transfection and Generation of Stable Clones 
For electrophoretic mobility shift assays (EMSA), 293T cells (106 cells/10 cm 
plate) were transiently transfected with the indicated plasmid DNA using the calcium 
phosphate method as described previously (Haque, 1997). A549 cells were 
transfected using Lipofectamine 2000 reagent (Invitrogen Carlsbad, CA) according 
to the manufacturer’s instructions.  All analyses were performed 48h post 
transfection. For generating stable clones, we transfected immortalized Prx II-/- MEF 
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cell lines with either vector or PrxI, Prx II, PrxI(C52S), PrxI(C83S), PrxI(C52/83S) or 
PrxII(C51S) using Lipofectamine 2000 (Haque et al., 2000), followed by 2 weeks of 
selection with 150 µg/ml hygromycin B (Invitrogen). 
4.3.4. EMSA and Luciferase Assay 
EMSA was performed using 10 µg proteins of whole cell extracts and 0.2 ng 
of 32P-labeled high-affinity STAT6-specific probe (Haque et al., 2000). Luciferase 
assay was performed as described previously (Haque et al., 1997).  
4.3.5. Intracellular ROS Assay 
ROS were measured fluorimetrically using CM-DCFHDA probe, as described 
previously in Chapter II. 
4.3.6. Immunoprecipitation and Immunoblotting 
Cells were harvested and incubated in lysis buffer for 30 min on ice. The 
lysates (500 µg protein per IP) were pre-cleared by incubation with 50 µl antiMouse 
IgG Beads from Mouse TrueBlot™ (eBioscience Inc,  San Diego, CA) and control 
IgG (2 µg, Santa Cruz) for 1 h to remove nonspecific binding. The lysates were then 
incubated with the primary antibody overnight at 4°C. 50 µl anti-Mouse IgG Beads 
from Mouse TrueBlot™ (eBioscience Inc, San Diego, CA) was then added and the 
samples were incubated for an additional 1 h. The anti-Mouse IgG Beads from 
Mouse TrueBlot™ was collected by centrifugation, washed and then boiled in 
sample buffer. The precipitated proteins were resolved by SDS-PAGE and detected 
by immunoblotting. Mouse TrueBlot™ ULTRA: Horseradish Peroxidase (HRP) 
antimouse IgG was used as secondary antibody. 
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4.3.7. Immunostaining 
PrxII expression in primary BMMC’s derived from PrxII+/+ cells was assessed 
by fluorescence microscopy. The cells were seeded on glass coverslips. When the 
cells were 70–80% confluent, they were fixed with cold methanol for 10 min at –20 
°C. Fixed cells were washed three times with PBS and blocked by incubation in PBS 
with 3% goat serum for 1 h at room temperature. The cells were washed once with 
0.3% PBS/goat serum and incubated overnight at 4°C with the anti–PrxII (diluted 
1:100) and anti-IL-4R (diluted 1:50) antibodies. The coverslips were washed three 
times with PBS and incubated for 1 h at room temperature with biotinylated 
secondary antibody and streptavidin-conjugated eFluor605 (red) for IL4Rα and 
secondary antibody conjugated with Alexafluor 488 (green) for Prx isoforms. 
Immunofluorescence images were obtained using a confocal laser-scanning 
microscope (Olympus). 
4.3.8. ROS-mediated Oxidation of PTP1B and Prx 
Briefly, after the indicated treatments, cell lysates were prepared using 
degassed buffers in the presence and absence of 100 mM iodoacetic acid (IAA) that 
irreversibly alkylated each reduced Cys in all proteins except for the catalytic 
cysteines of Prx II, which was reversibly oxidized to Cys-sulfenic acid (Cys-SOH) by 
IL-4 or H2O2 (positive control) treatment of cells. Individual Prx II containing both 
reversibly oxidized (Cys-SOH) and irreversibly alkylated Cys residues was 
immunoprecipitated and treated with DTT to reduce the Cys51-SOH.  After removal 
of unused DTT, Cys51-SH was irreversibly oxidized to Cys-SO3H (Cys-sulfonic acid) 
by treatment with pervanadate. This reaction product was then detected by Western 
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analysis using an antibody which recognizes both sulfenic and sulfonic forms of Prx 
II with high specificity (Woo et al., 2003a; Woo et al., 2003b). 
4.3.9. Statistical and Densitometric Analyses 
All experiments were performed at least three times, and data of one 
representative experiment are shown. Statistical differences between different 
groups were determined using paired Student’s t-test. EMSA and Western blot 
signals were quantified using ImageQuant (Molecular Dynamics).   
 
 
 
Table II: PCR Primer Sets for Cloning of Different Wild-Type and Mutant 
Antioxidant Enzymes. 
Purpose Gene Name Primer Sequences 
Cloning in 
pcDNA3-HA 
Prx I Forward: 5’-GGCCCCGGGGATCCGATCTTCAGGAAATGCAAAAATTGG-3’ 
Reverse: 5’-CGAGCTTCGAATTCTCATTCCTGCTTAGAGAAATAC-3’ 
Prx II Forward: 5’-GGCCCCGGGGATCCGAGCCTCCGGTAACGCGCG-3’ 
Reverse: 5’-CGAGCTTCGAATTCCTAATTGTGTTTGGAGAAATATTC-3’ 
Prx IV Forward: 5’- GAGGCCCCGGGGATCCGAGAGGCGCTGCCGCTGCTAG-3’ 
Reverse: 5’-AGATGCATGCTCGAGTCAATTCAGTTTATCGAAATACTTC-3’ 
Prx VI Forward: 5’- CGGGGATCCGAATTCGACCCGGAGGTCTGCTTCTCG-3’ 
Reverse: 5’-AGA TGC ATG CTC GAG TTA AGG CTG GGG TGT GTA GCG-3’ 
Point Mutation Prx I 
(C52S) 
Forward: 5’-CCCTCTTGACTTTACTTTTGTGTCTCCCACGGAGATCATTGCTTTC-3’ 
Reverse: 5’-GAAAGCAATGATCTCCGTGGGAGACACAAAAGTAAAGTCAAGAGGG-3’ 
Prx I 
(C83S) 
Forward: 5’-GCTTCTGTGGATTCTCACTTCTCTCATCTGGCATGGATTAACACAC-3’ 
Reverse: 5’-GTGTGTTAATCCATGCCAGATGAGAGAAGTGAGAATCCACAGAAGC-3’ 
Prx II 
(C51S) 
Forward: 5’-CCTCTGGACTTCACTTTTGTGTCCCCCACCGAGATCATCGCG-3’ 
Reverse: 5’-CGCGATGATCTCGGTGGGGGACACAAAAGTGAAGTCCAGAGG-3’ 
Prx II 
(C172S) 
Forward: 5’-CAGACGAGCATGGGGAAGTTTCTCCCGCTGGCTGGAAGCC-3’ 
Reverse: 5’-GGCTTCCAGCCAGCGGGAGAAACTTCCCCATGCTCGTCTG-3’ 
Cloning  
in pcDNA3.1/V5-
HisA 
CAT Forward: 5’- TGGCTAGTTAAGCTTGCCACCATGGCTGACAGCCGGGATC-3’  
Reverse: 5’- TGGCTAGTTAAGCTTGCCACCATGGCTGACAGCCGGGATC-3’  
SOD1 Forward: 5’- TGGCTAGTTAAGCTTGCCACCATGGCGACGAAGGCCGTG-3’  
Reverse: 5’- CCCTCTAGACTCGAGTTGGGCGATCCCAATTACAC-3’  
SOD2 Forward: 5’- TGGCTAGTTAAGCTTGCCACCATGTTGAGCCGGGCAGTGTG-3’  
Reverse: 5’- CCCTCTAGACTCGAGCTTTTTGCAAGCCATGTATCTTTC-3’  
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4.4. Results 
4.4.1. Redox State of Cells Controls the Magnitude of IL-4-induced ROS 
Generation, Receptor Activation, Signal Transduction and Gene Expression 
We have demonstrated in Chapter III that ROS generated by activated 
receptors of EPO, IL-3 or TNF-α markedly amplified, in trans, the activation of IL-4 
receptor and consequent signal transduction. This ROS-mediated cytokine cross-
talk, which likely occurred due to the diffusion of ROS from the site of generation to 
the surrounding environment, raised the possibility that the redox state of a cell may 
control the magnitude of IL-4 (or other cytokine) receptor activation and subsequent 
signal transduction. To address this possibility, we took both pharmacologic and 
molecular genetic approaches. 
We measured IL-4-induced STAT6 activation and ROS generation in A549 
cells pretreated with buthionine-S,R-sulphoximine (BSO) (Friedman et al., 1989), a 
glutathione (reduced) depleting agent, 3-amino-1,2,4-trizole (ATZ) (Kingma et al., 
1996), an inhibitor of catalase, sodium diethylthiocarbamate trihydrate (DETC) 
(Vanin et al., 1999), an inhibitor of SOD and N-Acetyl Cysteine (NAC) (Dobashi et 
al., 2001), a scavenger of ROS (Figure 4.1A & B). We observed that BSO, ATZ and 
DETC significantly increased IL-4-induced activation of STAT6, as measured by 
EMSA (Figure 4.1B). In consistence with this, NAC markedly decreased IL-4-
induced ROS generation and STAT6 activation (Figure 4.1A & B). However, IL-4-
induced ROS generation was not significantly changed by BSO, ATZ or DETC 
(Figure 4.1A).  
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Next, A549 cells were transiently transfected with expression constructs of 
catalase, GPx1 and SOD2 and 48 h post-transfection, IL-4-induced ROS generation 
and STAT6 activation were measured (Figure 4.2A & B). Figure 4.2B reveals that IL-
4-induced STAT6 activation was markedly reduced in cells over-expressing these 
antioxidant enzymes. Over expression of catalase and GPx1 but not SOD2 
moderately reduced the amounts of IL-4-generated ROS in A549 cells (Figure 4.2A). 
In chapter II, we have demonstrated that diphenylene idonium, an inhibitor of 
flavoprotein activity which blocks ROS production by the mitochondrial electron 
transport chain and NOX/DUOX family enzymes, also reduced IL-4-induced 
activation of STAT6.  Taken together, these data suggest that alterations in cellular 
antioxidants may regulate the magnitude of IL-4-dependent signal transduction. To 
confirm this notion, we measured IL-4-induced ROS generation and STAT6 
activation in embryonic fibroblasts derived from catalase-knockout and wild type 
mice (Figure 4.3A & B). We observed that catalase-deficiency significantly increased 
IL-4-induced ROS generation and STAT6 activation. The change in STAT6 
activation measured by EMSA was confirmed by Western analysis for tyrosine-
phosphorylated STAT6 (Figure 4.3B, middle panel).  Moreover, MEFs derived from 
GPx1-knockout and catalase and GPx1-double knockout mice also exhibited 
significant increase in IL-4-induced ROS generation and STAT6 activation, when 
compared with wild-type MEFs (Figure 4.4A & B; Figure 4.5A & B). Collectively, 
these data reveal that antioxidant enzymes are involved in IL-4 receptor activation 
and signal transduction.  
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The above observations prompted us to examine whether Prx family enzymes 
are involved in IL-4 receptor activation and signal transduction. IL-4 receptor 
activation occurs on the cytoplasmic side of the plasma membrane. Four Prx’s, 
namely Prx I, II, IV and VI, which are reported to be expressed in the cytosol, were 
overexpressed in A549 cells, and measured IL-4-induced ROS generation and 
STAT6 activation measured (Figure 4.6A & B).  We found that Prx II, IV and VI but 
not Prx I significantly reduced the levels of IL-4-generated ROS and IL-4-induced 
STAT6 activation (measured by EMSA and Western analysis). Figure 4.6B (bottom 
panel) revealed that the exogenous Prx proteins were expressed at comparable 
levels. Furthermore, we found that overexpression of Prx II, IV and VI, but not Prx I, 
significantly attenuated IL-4-dependent STAT6-reponsive gene expression in a time-
dependent fashion, as measured by luciferase reporter assay (Figure 4.7). This 
reporter construct has been described previously in chapter II. Taken together, these 
data clearly suggest that Prx II, IV and VI act as negative regulators of IL-4 signaling.  
To further define the role of Prx II in IL-4 signaling, we treated MEFs and 
primary splenocytes derived from Prx II-KO (Choi, 2005; Lee, 2003; Moon, 2004) 
and wild-type mice. Cells were treated with IL-4 and STAT6 activation measured by 
EMSA and western analysis. The data revealed that Prx II-deficiency markedly 
upregulated IL-4-dependent STAT6 activation in both MEFs (Figure 4.8, A & B) and 
splenocytes (Figure 4.8C & D). Moreover, we found that Prx II-deficient cells 
produced significantly greater amounts of ROS than wild-type cells in response to IL-
4 stimulation (Figure 4.8A & C). These data confirmed that Prx II acts as a negative 
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regulator of IL-4-dependent signal transduction in both hematopoietic and non-
hematopoietic cell. 
4.4.2. Prx II, IV and VI Physically Associate with IL-4Rα 
To understand the spatial, biochemical and structural basis of antioxidant 
enzyme-mediated negative regulation of IL-4 receptor activation and signal 
transduction, we performed the following experiments.  
Mouse bone marrow-derived macrophages grown on coverslips were 
stimulated with murine IL-4 for 5 min or left untreated.  Fixed cells were stained with 
anti-IL-4Rα and anti-Prx antibodies, as indicated. Prx localization was detected by 
green fluorescence and IL-4Rα chain by red fluorescence; yellow fluorescence 
represented their co-localization.  Figure 4.9 revealed that IL-4Rα co-localized with 
Prx II, IV and VI, but not Prx I, in IL-4-stimulated mouse bone marrow-derived 
macrophages. In the absence of IL-4 stimulation, co-localization of IL-4Rα with none 
of these antioxidant enzymes was detected in murine bone marrow derived 
macrophages. 
 In humans, Prx I and Prx II have 91% homology and 78% identity in their 
amino acid sequences (Figure 4.10).  A recent study has demonstrated that Prx I 
functions well as a molecular chaperone than as a peroxidase, whereas Prx II is a 
better peroxidase (Lee, 2007).  This differential function of Prx I is attributed to the 
presence of unique Cys83 and by the observation that a mutant Prx I, in which Ser 
replaces Cys83 (Prx I C83S), start behaving as a Prx II protein. These structure-
function studies were performed with purified Prx proteins (Lee, 2007). 
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To explore why Prx I failed to interact with and/or downregulate IL-4 receptor, 
we generated the mutant PrxI (C52S), in which the catalytic Cys52 was replaced by a 
Ser, PrxI (C83S), in which the catalytic Cys83 was replaced by a Ser, PrxI (C52/83S), 
in which both catalytic Cys52 and Cys83 were replaced by Ser and PrxII (C51S), in 
which the catalytic Cys51 was replaced by a Ser constructs (Figure 4.11). We stably 
transfected immortalized Prx II-/- MEF cell lines with either vector or PrxI, Prx II, 
PrxI(C52S), PrxI(C83S), PrxI(C52/83S) or PrxII(C51S), and clones were selected in 
the presence of 150 µg/ml hygromycin B. We found after knocking in wild type PrxII 
in  Prx II-/- MEF, there was a substantial downregulation of activated STAT6 signal 
which was comparable to the  STAT6 levels in Prx II+/+ MEFs (Figure 4.12, lane 4), 
but failed to do so (Figure 4.12, lane 5) where the transgene expressed was 
PrxII(C51S). In addition when PrxI(C83S) was knocked in (Figure 4.12, lane 6), IL-4-
mediated STAT6 activation was downregulated ,which was not seen with the wild 
type PrxI construct (Figure 4.12, lane 9). 
To examine whether Prx II, IV and VI physically associates with the IL-4 
receptor complexes, co-immunoprecipitation (Co-IP) experiments were performed 
using 293T cells which were transiently transfected with V5-tagged human IL-4Rα 
and HA-tagged Prx I, II, IV or VI. We found that Prx II (Figure 4.13, lane 6), Prx IV 
(Figure 4.13, lane 8) and VI (Figure 4.13, lane 9) but not Prx I (Figure 4.13, lane 2) 
formed complexes with the IL-4Rα. We found that Prx I C83S formed a complex with 
the IL-4Rα, while the catalytically inactive mutants Prx I C52S and C52S/C83S were 
unable to interact (Figure 4.13, lanes 4 and 5). A catalytically inactive Prx II C51S 
which failed to downregulate IL-4-induced STAT6 activation, was also unable to bind 
126 
 
(Figure 4.13, lane 7).  A similar Co-IP experiment was performed to determine 
whether catalase, GPx1 or SOD2 formed complexes with the IL-4Rα; revealing that 
none of these antioxidant proteins was present in the IL-4 receptor complex (Figure 
4.14). 
4.4.3. IL-4-generated ROS induces oxidative inactivation of Prx II and Prx II-
deficiency upregulates PTP1B oxidation in IL-4 stimulated cells 
The catalytic Cys of Prx II, like those of other Prx’s, may be hyper-oxidized to 
Cys-sulfenic acid, which is slowly reduced to the active thiol form in an ATP-
dependent process (Rhee et al., 2005). Because Prx II formed complex with IL-4Rα, 
we examined whether the catalytic Cys51 of Prx II was oxidized by IL-4-generated 
ROS. The N-terminal conserved catalytic Cys of Prx I through Prx IV is located 
within a conserved motif, Asp-Phe-Trp-Phe-Val-Cys-Pro-Thr-Glu-Ile (Chae et al., 
1994b). We treated A549 cells with IL-4 or H2O2 for 5 min (as a positive control). 
Oxidation of the catalytic Cys51 of Prx II was measured using an antibody raised 
against a peptide including the oxidized catalytic Cys residue conserved in PrxI 
through Prx IV, following the method of Woo et al. (Woo et al., 2003a; Woo et al., 
2003b). Our experiments revealed that IL-4-generated ROS induced the oxidative 
inactivation of Prx II in A549 cells (Figure 4.15).  
Because Prx II-deficient cells, which produced higher levels of ROS compared 
to wild-type cells upon IL-4 stimulation, exhibited an enhanced activation of STAT6 
(Figure 4.14), we reasoned that Prx II deficiency would lead to enhanced PTP1B 
oxidation by IL-4. To test this possibility, we treated MEFs derived from wild-type 
and Prx II-deficient mice with IL-4 or H2O2 (positive control), and measured the 
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oxidation levels of PTP1B, as described earlier in Chapter III. The data show that 
Prx II deficiency indeed led to a marked increase in IL-4-induced oxidation of 
PTP1B, suggesting that Prx II-dependent negative regulation of IL-4 signaling was 
mediated by elimination of IL-4-generated ROS which oxidatively inactivated PTP1B 
(Figure 4.16A & B).  
 
 
 
 
 
Figure 4.1: Effects of Inhibitors of Antioxidant Enzymes and N-Acetyl Cysteine 
on IL-4-induced ROS Generation and STAT6 Activation. 
(A) NAC downregulates IL-4-induced ROS generation. A549 cells were pretreated 
for 2 hr with BSO (50 µM), ATZ (20 mM), DETC (20 µM), NAC (5 mM), or DMSO, 
and ROS were measured after IL-4 (20 ng/ml) stimulation. RFU represent mean ± 
SE (n=3). 
(B) Treatment with NAC significantly downregulates IL-4-dependent STAT6 
activation. A549 cells were pretreated as in (A), and treated with IL-4 (20 ng/ml) for 5 
min. Cell extracts were subjected to EMSA and RSI quantified. 
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Figure 4.2: Ectopic Expression of Global Antioxidant Proteins Reduces IL-4-
dependent ROS Generation and STAT6 Activation. 
(A) Overexpression of antioxidant proteins downregulates IL-4-mediated ROS 
generation. A549 cells were transfected with 4.0 µg of catalase, Gpx1, SOD2, or 
empty vector. After 48 hr, IL-4-mediated ROS were measured and RFU plotted as 
mean ± SE (n=3). 
(B) IL-4-mediated STAT6 activation is downregulated following overexpression of 
catalase, Gpx1, or SOD2 in cells. A549 cells were transfected as in (A). After 48 hr, 
cells were stimulated with IL-4 (20 ng/ml) for 5 min. Cell extracts were subjected to 
EMSA and RSI quantified. 
129 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Catalase Deficiency Increases IL-4-induced ROS Generation and 
STAT6 Activation. 
(A) Catalase deficiency increases IL-4-induced ROS generation in MEFs. Catalase-
deficient (Cat-/-) and wild-type (Cat+/+) MEFs were treated with IL-4 (20 ng/ml), ROS 
measured and RFU plotted as mean ± SE (n=3; “*” indicates p < 0.05).  
(B) Catalase deficiency increases IL-4-dependent STAT6 activation. Catalase-
deficient (Cat-/-) and wild-type (Cat+/+) MEFs were treated with IL-4 (20 ng/ml) for 5 
minutes, cell extracts were subjected to EMSA or immunoblot analysis (with anti-
phospho-Tyrosine641-STAT6) and RSI quantified. Immunoblot analysis with anti-
STAT6 served as loading control. 
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Figure 4.4: Gpx1 Deficiency Increases IL-4-induced Signaling. 
(A) Gpx deficiency increases IL-4-induced ROS generation in MEFs. Gpx1-deficient 
(Gpx1-/-) and wild-type (Gpx1+/+) MEFs were treated with IL-4 (20 ng/ml) for 5 
minutes and ROS measured and RFU plotted as mean ± SE (n=3). 
(B) Gpx1 deficiency increases IL-4-dependent STAT6 activation. Gpx1-deficient 
(Gpx1-/-) and wild-type (Gpx1+/+) MEFs were treated with IL-4 (20 ng/ml) for 5 
minutes, cell extracts were subjected to EMSA and immunoblot analysis (with anti-
phospho-Tyrosine641-STAT6) and RSI quantified. Immunoblot analysis with anti-
STAT6 served as loading control. 
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Figure 4.5: Catalase and Gpx1 Double Knockout Mice Show Increased IL-4 
Signaling. 
(A) Catalase and Gpx1 deficiency co-operatively increases IL-4-induced ROS 
generation in MEFs. Catalase and Gpx-deficient (Cat-/- Gpx-/-) and wild-type MEFs 
were treated with IL-4 (20 ng/ml) for 5 minutes and ROS were measured and RFU 
plotted as mean ± SE (n=3; “**” indicates p < 0.01). 
(B) Catalase and Gpx1 deficiency increases IL-4-dependent STAT6 activation. 
Catalase and Gpx-deficient (Cat-/- Gpx-/-) and wild-type MEFs were treated with IL-4 
(20 ng/ml) for 5 minutes, cell extracts were subjected to EMSA or immunoblot 
analysis (with anti-phospho-Tyrosine641-STAT6) and RSI were quantified. 
Immunoblot analysis with anti-STAT6 served as loading control. 
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Figure 4.6: Prx II, Prx IV, and Prx VI but not PrxI Downregulates IL-4 Signaling. 
(A) Overexpression of Prx II, Prx IV and Prx VI, but not Prx I downregulates IL-4-
mediated ROS generation. A549 cells were transfected with 4.0 mg of Prx I-HA, Prx 
II-HA, Prx IV-HA, Prx VI-HA, or empty vector. After 48 hr, IL-4-generated ROS were 
measured and RFU plotted as mean ± SE (n=3; “*” indicates p < 0.05; “**” indicates 
p < 0.01). 
(B) IL-4-mediated STAT6 activation is downregulated following overexpression of 
Prx II, Prx IV and Prx VI, but not Prx I. A549 cells were transfected as in (A). After 48 
hours cells were stimulated with IL-4 (20 ng/ml) for 5 minutes, cell extracts were 
subjected to EMSA and immunoblot analysis as indicated and RSI quantified. 
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Figure 4.7: Prx II, Prx IV, and Prx VI Downregulates STAT6-responsive Gene 
Expression.  
A549 cells were co-transfected with 2.5 µg of Prx I, Prx II, Prx IV, or Prx VI and 2.5 
µg of STAT6-responsive luciferase construct (TPU474), or empty vector (TPU222). 
After 24 hr, transfected cells were stimulated with IL-4 (20 ng/ml) for indicated 
lengths of time or left untreated, and luciferase activity was measured. Normalized 
luciferase activities in arbitrary units (AU) plotted as mean ± SE (n=3). 
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Figure 4.8: Prx II is a Negative Regulator of IL-4 Signaling. 
(A) Prx II deficiency increases IL-4-induced ROS generation in MEFs. Prx II-deficient 
(Prx II-/-) and wild-type (Prx II+/+) MEFs (immortalized) were treated with IL-4 (20 
ng/ml). ROS were measured and RFU plotted as mean ± SE (n=3; “*” indicates p < 
0.05). 
(B) Prx II deficiency increases IL-4-dependent STAT6 activation in MEFs. Prx II-
deficient (Prx II-/-) and wild-type (Prx II+/+) MEFs (immortalized) were treated with IL-4 
(20 ng/ml) for 5 minutes. Cell extracts were subjected to EMSA and immunoblot 
analysis (with anti-phospho-Tyrosine641-STAT6), and RSI were quantified. 
Immunoblot analysis with anti-β-actin served as loading control. Immunoblot analysis 
with anti-Prx II confirmed the knock-out status of the Prx II-/- MEFs. 
(C) Prx II deficiency increases IL-4-induced ROS generation in mouse primary 
splenocytes. Splenocytes isolated from Prx II-/- and Prx II+/+ were treated with IL-4 
(20 ng/ml) for 5 minutes, ROS were measured and RFU plotted as mean ± SE (n=3; 
“*” indicates p < 0.05). 
(D) Prx II deficiency increases IL-4-dependent STAT6 activation in mouse primary 
splenocytes. Splenocytes isolated from Prx II-/- and Prx II+/+ were treated with IL-4 
(20 ng/ml) for 5 minutes. Cell extracts were subjected to EMSA and immunoblot 
analysis (with anti-phospho-Tyrosine641-STAT6) and RSI quantified. Immunoblot 
analysis with anti-STAT6 served as loading control. Immunoblot analysis with anti-
Prx II confirmed the knock-out status of the splenocytes isolated from Prx II-/- mice. 
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Figure 4.9: Prx II, Prx IV, Prx VI, but not Prx I Co-localizes with the IL-4 
Receptor. 
Bone marrow derived primary macrophages from wild-type mice, grown on 
coverslips, were stimulated with murine IL-4 (20 ng/ml) for 5 min or left untreated. 
The cells were stained with anti-mouse IL-4Rα antibody and with Prx isoform 
specific antibodies. For detection of Prx isoforms, rabbit polyclonal primary 
antibodies was used followed by secondary antibody conjugated with Alexafluor 488 
(that gives green signal). For detection of IL-4Rα, cells were incubated with rat 
monoclonal primary antibody followed by incubation with biotinylated secondary 
antibody and streptavidin-conjugated eFluor605 (that gives red fluorescence). The 
slides were mounted using Vectashield with DAPI (to stain the nuclei with blue). 
Images were obtained with original magnification set at 63X, with representative 
images shown here.  The slides were visualized using a fluorescence microscope. 
The different signals detected are: IL-4Ra (red), Prx II (green) and nuclei (blue).The 
yellow regions represent areas of co-localization. 
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Figure 4.10: Schematic Representation of the Prx I and Prx II Protein. 
 
 
 
 
 
Figure 4.11: Schematic Representation of the Prx I and Prx II Deletion Mutants. 
The mutants were generated using Quick Change XL Site-Directed Mutagenesis Kit 
(Stratagene) following the manufacturer‘s instructions. 
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Figure 4.12: Knocking-in of Prx Isoforms and Mutants to Prx II-/- MEFs Altered 
IL-4-dependent STAT6 Activation. 
 
(A) Immortalized Prx II-/- MEFs were stably transfected with either vector or Prx I, 
Prx II, PrxI(C52S), PrxI(C83S), PrxI(C52/83S) and PrxII(C51S), and clones were 
selected in the presence of hygromycin B. Representative  stable clones of Prx II-/- 
MEFs  were selected and was examined for IL-4-induced ROS production. RFU are 
plotted as mean ± SE, (n=3) (* = P < 0.05; ** = P < 0.01).  
 
(B) Stable clones were made as described in (A). Selected pools were treated with 
IL-4 (20 ng/ml) for 5 min and cell extracts subjected EMSA, and RSI quantified. 
 
 
(B) 
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Figure 4.13:  Prx II, Prx IV, Prx VI, but not Prx I Physically Associates with the 
IL-4 Receptor. 
293T cells were co-transfected with V5-tagged human IL4Ra (2.0 mg) and 4.0 mg 
wild-type Prx I-HA, mutant Prx I(C83S)-HA, mutant Prx I(C52S)-HA,  double mutant 
Prx I(C52/C83S)-HA, wild-type Prx II-HA, mutant Prx II(C51S)-HA, Prx IV-HA, Prx 
VI-HA, or empty vector constructs. After 48 hr, cell lysates (1 mg protein) were 
immunoprecipitated using anti-V5, or anti-HA and the immune complexes subjected 
to immunoblot analysis with anti-HA and anti-V5 antibody, as indicated.   
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Figure 4.14: Specificity of Prx II is maintained by Direct Interaction with IL-4 
Receptor. 
293T cells were co-transfected with human IL4Rα-V5 (2.0 mg) along with catalase, 
Gpx, SOD2, Prx II-HA, or empty vector (4 mg) constructs. After 48 hr, cell lysates (1 
mg protein) were immunoprecipitated using anti-V5, and immune complexes 
subjected to immunoblot analysis with a cocktail of anti-catalase, anti-SOD2, anti-
Gpx1 and anti-Prx II antibodies. 
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Figure 4.15: IL-4 Induces Prx II Oxidation.  
IL-4-stimulation oxidizes Prx II, but not Prx I. A549 cells were treated for 5 minutes 
with 20 ng/ml of IL-4, with 3 mM H2O2 (positive control), or were left untreated. Cell 
lysates were prepared in the presence (upper panel) or absence (lower panel) of IAA 
and immunoprecipitated with anti-Prx I or anti-Prx II. Immune complexes were 
subjected to immunoblot analysis using a monoclonal antibody raised against 
oxidized Prx active site. 
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Fig 4.16: Prx II-deficiency Results in Increased IL-4-induced PTP1B Oxidation.  
Immortalized MEFs (A) and splenocytes (B) derived from PrxII+/+ (wild type) and 
PrxII-/- mice were treated for 5 minutes with 20 ng/ml of IL-4, with 3 mM H2O2 
(positive control), or were left untreated. Cell lysates were prepared in the presence 
(upper panel) or absence (lower panel) of IAA and immunoprecipitated with anti-
PTP1B, and the immune complexes were subjected to immunoblot analysis with a 
monoclonal antibody that recognizes oxidized-PTP active site.  
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4.5. Discussion 
Cell signaling by hematopoietin and interferon family of cytokines is 
mediated by tyrosine phosphorylation of their receptors and cognate downstream 
signaling proteins (Haque and Sharma, 2006). Tyrosine phosphorylation is a 
reversible protein modification in which the forward reaction is catalyzed by PTK 
and the reverse reaction by PTP. Previous work from our laboratory and others 
has demonstrated that cytokine receptor associated PTP-activity plays a primary 
role in the negative regulation of cytokine receptor activation, and subsequent 
signal transduction and gene expression (Haque et al., 1995; Haque et al., 1998; 
Haque and Sharma, 2006; Haque et al., 1997; Pao et al., 2007). In chapter III, 
we have shown that PTP1B dephosphorylated and deactivated the IL-4 receptor 
in both hematopoietic and non-hematopoietic cells. We have also shown that IL-4 
stimulation produced ROS which oxidatively inactivated PTP1B, thereby 
promoting IL-4 receptor activation and subsequent signal transduction.  
Since ROS are capable of diffusing away from the sites of generation and 
produce oxidative damage to cells, we hypothesized that cellular antioxidant 
enzymes might participate as scavengers of IL-4-generated ROS. In testing this 
hypothesis, we found that cellular antioxidant enzymes including SOD2, catalase, 
GPx1, Prx II, Prx IV and Prx VI were able to attenuate ROS-mediated 
amplification of IL-4 receptor activation and its downstream signaling pathways. 
Interestingly, our data also revealed that among these enzymes, Prx II, Prx IV 
and Prx VI functioned as specific scavengers of IL-4-generated ROS by forming 
complexes with activated IL-4 receptor. In contrast, SOD2, catalase and GPx1 
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did not co-localize or physically associate with the activated IL-4 receptor, 
thereby functioning as global antioxidants, likely protecting cells form oxidative 
damage and preventing ROS-mediated cytokine cross-talks. Therefore, these 
findings suggest that the global redox state of cells may regulate the magnitude 
of amplification of IL-4 receptor activation which is mediated by IL-4- or other 
cytokine-generated ROS.   
Currently experiments are underway to confirm this notion. If this notion is 
found to be correct, then the redox state of cells will be reflected in the outcome 
of cytokine action.  Of note, our laboratory found that hypoxia, which also 
generated ROS, promoted cytokine-dependent activation of STAT3 in 
glioblastoma multiforme cells (unpublished data). Herein, we presented data that 
clearly demonstrated the specificity of the ROS-scavenging function of Prx II, Prx 
IV and Prx VI in IL-4 stimulated cells, by detecting their presence in the activated 
IL-4 receptor complex. Consistent with our findings, a recent report has shown 
that Prx II physically associates with activated the PDGF receptor and attenuates 
its activation (Choi et al., 2005).  We have shown that Prx II became oxidatively 
inactivated by IL-4-generated ROS, thus decreasing the amounts of ROS 
generated by IL-4 stimulated cells. Oxidation of catalytic Cys51 in Prx II is 
required for its ROS-scavenging activity (Rhee et al., 2000; Rhee et al., 2005). 
So, the observation described above is consistent with the observed increase in 
the amount of ROS detected in IL-4 stimulated, Prx II-deficient cells compared 
with wild-type cells. Importantly, these correlated well with the increase in STAT6 
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activation, a readout of IL-4 receptor activation (Haque and Sharma, 2006; 
Nelms et al., 1999).  
To further understand the structural basis of the ROS-scavenging function 
of Prx II in IL-4 stimulated cells, we compared the roles of two highly homologous 
(91% homology, and 78% identity in amino acid sequences) Prx proteins, namely 
Prx I and Prx II.  Although both the proteins were localized in the cytoplasm, Prx I 
failed to associate with the IL-4 receptor complex and scavenge IL-4-generated 
ROS.  We hypothesized that this was due to structural feature(s) unique to the 
Prx I protein.  The catalytic (peroxidase) activity of Prx I or Prx II, in the presence 
of H2O2, is mediated by the formation of a transient intermolecular disulfide bond 
between the catalytic Cys (residue 52 in Prx I and 51 in Prx II) and the ‘resolving’ 
Cys (residue 173 in Prx I and 172 in Prx II); the disulfide bond is then reduced to 
Cys-SH by thioredoxin which functions as a disulphide oxidoreductase (Lee et 
al., 2007; Rhee et al., 2000; Rhee et al., 2005). In contrast, the chaperone 
activity of Prx I is mediated by the formation of a decameric structure, which is 
stabilized by the formation of a disulfide bond between Cys83 of Prx I (Lee et al., 
2007). Thus, Prx I exhibits more chaperone function than peroxidase activity, 
whereas Prx II, due to the absence of Cys which is equivalent Cys83 of Prx I, 
functions more as a peroxidase than a chaperone. This conclusion is based on 
the structural studies using the purified proteins (Lee et al., 2007).  Our data 
using mutant forms of Prx I (C83S, C52S, C52S/C83S) and Prx II (C51S) 
revealed that the peroxidase activity of Prx II was required for its interaction with 
the IL-4 receptor complex, and that the Ser substitution of Cys83 transformed Prx 
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I to a functional Prx II. These observations were then substantiated by the 
restoration of Prx II function in Prx II-deficient cells by knocking in either the wild-
type Prx II or the C83S mutant Prx I. Moreover, co-immunoprecipitation data 
confirmed that the C83S mutant Prx I acted as a functional Prx II by physically 
associating with the IL-4 receptor complex.  Currently studies are underway to 
understand the roles of Prx proteins in vivo in IL-4-dependent immune responses 
including T helper cell differentiation and T cell receptor signaling, using Prx KO 
mice.  
Based on the findings described in this thesis, we may conclude that 
inactivation of receptor-associated PTP-activity by cytokine-generated ROS is a 
physiologic mechanism for the amplification of cytokine receptor activation in 
both cis and in trans, which is negatively regulated by antioxidant enzyme-
mediated elimination of ROS in cytokine-stimulated cells, and thus, antioxidant 
enzymes restore the homeostasis of cytokine signaling in mammalian cells. 
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CHAPTER V 
SUMMARY AND SIGNIFICANCE 
 
 
The objective of this study was to elucidate the molecular mechanisms 
underlying homeostatic regulation of IL-4 mediated cell signaling. To accomplish 
this, we have demonstrated that immediately upon binding with its cognate 
receptor, IL-4 generated ROS in variety of cell types through IRS-PI3K-Rac1-
NOX1 pathway. In addition, we also found that in human A549 cells, IL-4 
receptor induced an intracellular calcium flux via IRS-PI3K-PLC-γ pathway, which 
in turn induces PKC-dependent activation of NOX5L that generated reactive 
oxygen species (ROS). However, ROS were not required for the initiation of IL-4 
receptor activation but they actively participated in promoting receptor activation 
and signal amplification. Additionally, we have identified a ubiquitously expressed 
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phosphatase, PTP1B that associated and negatively regulated IL-4 receptor 
activation and subsequently became oxidatively inactivated by IL-4-mediated 
ROS. Further, we found that ROS generated by other cytokine receptors also 
promoted IL-4 receptor activation. These data reveal that inactivation of receptor-
associated PTP-activity by cytokine-generated ROS is a physiologic mechanism 
for the amplification of cytokine receptor activation both in cis and in trans, 
unfolding a novel means of cytokine cross-talk. In addition, we have shown that 
anti oxidant enzymes, including SOD2, catalase, GPx1, Prx II, Prx IV and Prx VI,  
reduced the steady state level of ROS produced by IL-4.  Unlike, SOD2, catalase 
and GPx1, Prx II, IV and VI physically interacted with IL-4Rα and thereby 
prevented the inactivation of PTP1B by catalytically reducing ROS.  
It was long conceived that the cytokine-activated Jak-STAT pathway 
operates directly from the cell surface to the nucleus via DNA-protein and 
protein-protein interactions without involving any second messengers. This study 
unfolded, for the first time to our knowledge, a role for second messengers 
(ROS) in the amplification of the IL-4-activated Jak-Stat signaling pathway. 
Another interesting aspect of this study was cytokine crosstalk, which holds high 
potential and may help us understand the underlying side effects of cytokine 
therapies in a variety of diseases. 
Further, antioxidant enzyme-mediated catalytic reduction of ROS 
generated by IL-4-stimulation of cells reiterates the importance of antioxidant 
proteins for maintaining cellular homeostasis. IL-4 has crucial role in the 
pathogenesis of allergic diseases including the allergic asthma that affects about 
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16.2 million people in the US and 130 million more in rest of the world. This study 
provides new insights into the mechanisms of IL-4 signaling, which may help 
design new therapies for these diseases. 
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Figure 5.1: Working Model of Redox Regulation of IL-4-meidated Cell 
Signaling. 
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